Gonorrhoea

Magnus Unemo[1,2], H Steven Seifert[3], Edward W. Hook III[4], Sarah Hawkes[5], Francis Ndowa[6] and Jo-Anne R. Dillon[7,8]*

Abstract | The bacterium *Neisseria gonorrhoeae* causes the sexually transmitted infection (STI) gonorrhoea, which has an estimated global annual incidence of 86.9 million adults. Gonorrhoea can present as urethritis in men, cervicitis or urethritis in women, and in extragenital sites (pharynx, rectum, conjunctiva and, rarely, systemically) in both sexes. Confirmation of diagnosis requires microscopy of Gram-stained samples, bacterial culture or nucleic acid amplification tests. As no gonococcal vaccine is available, prevention relies on promoting safe sexual behaviours and reducing STI-associated stigma, which hinders timely diagnosis and treatment thereby increasing transmission. Single-dose systemic therapy (usually injectable ceftriaxone plus oral azithromycin) is the recommended first-line treatment. However, a major public health concern globally is that *N. gonorrhoeae* is evolving high levels of antimicrobial resistance (AMR), which threatens the effectiveness of the available gonorrhoea treatments. Improved global surveillance of the emergence, evolution, fitness, and geographical and temporal spread of AMR in *N. gonorrhoeae*, and improved understanding of the pharmacokinetics and pharmacodynamics for current and future antimicrobials in the treatment of urogenital and extragenital gonorrhoea, are essential to inform treatment guidelines. Key priorities for gonorrhoea control include strengthening prevention, early diagnosis, and treatment of patients and their partners; decreasing stigma; expanding surveillance of AMR and treatment failures; and promoting responsible antimicrobial use and stewardship. To achieve these goals, the development of rapid and affordable point-of-care diagnostic tests that can simultaneously detect AMR, novel therapeutic antimicrobials and gonococcal vaccine(s) in particular is crucial.

The sexually transmitted infection (STI) gonorrhoea remains a major public health concern globally. The aetiological agent of gonorrhoea, the bacterium *Neisseria gonorrhoeae* (the gonococcus), generally causes mucosal infections of the urogenital tract, predominantly infecting columnar and transitional epithelia, although it can also attach to the stratified squamous epithelium of the ectocervix[1,2]. Such *N. gonorrhoeae* infections most frequently result in urethritis in men and cervicitis in women, but urethritis in women is also observed[3,4]. This obligate human host-adapted pathogen was described for the first time by Albert Neisser in Gram-stained microscopy of urethral discharge in 1879 (REF.[5]). *N. gonorrhoeae* is a diplococcal (that is, it is typically composed of two joined cells with the adjacent sides flattened, resulting in a characteristic kidney or coffee bean appearance on microscopy), Gram-negative microorganism; it belongs to the bacterial class Betaproteobacteria and the family Neisseriaceae, and has been co-evolving with its human host for centuries. The family Neisseriaceae comprises the genus *Neisseria* and other genera such as *Kingella* and *Eikenella*[6–8]. The *Neisseria* genus currently consists of at least 23 species, of which about half are human-restricted species, some are animal-restricted and some can be isolated from mucosal surfaces in both humans and animals[8]. *N. gonorrhoeae* is genomically, morphologically and phenotypically closely related to the other pathogenic *Neisseria* species, *Neisseria meningitidis*, which is typically carried as a commensal in the (naso) pharynx of 10–15% of the general population but occasionally causes fatal septicaemia and/or meningitis[6,8–10]. *N. gonorrhoeae* is also related to several other commensal *Neisseria* species that reside particularly in the pharynx. Despite containing many of the pathogenicity and virulence factors of *N. gonorrhoeae* and *N. meningitidis*, the commensal *Neisseria* species, from which these two pathogenic *Neisseria* species have evolved, do not normally cause pathology[9] as they are unable to induce substantial polymorphonuclear leukocyte (PMNL)-based inflammation and lack several additional factors and mechanisms of interacting with host molecules, cells and tissues[11]. The pathogenesis and pathophysiology of *N. gonorrhoeae* have been studied for decades; however, detailed knowledge regarding many fundamental properties is lacking.

*e-mail: magnus.unemo@regionorebrolan.se

https://doi.org/10.1038/s41572-019-0128-6

Author addresses

[1]World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
[2]National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden.
[3]Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
[4]Departments of Medicine, Epidemiology and Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
[5]Institute for Global Health, University College London, London, UK.
[6]Skin and Genitourinary Medicine Clinic, Harare, Zimbabwe.
[7]Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
[8]Vaccine and Infectious Disease Organization — International Vaccine Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

The majority of men with gonococcal urethritis are symptomatic, but substantially fewer women with urogenital gonorrhoea are symptomatic and, when present, symptoms are nonspecific. Nevertheless, signs of infection can be identified in most women with urogenital gonorrhoea. Rectal and pharyngeal gonorrhoea, which is mostly asymptomatic, are most frequently diagnosed in men who have sex with men (MSM), but are not rare in women either. Disseminated gonococcal infections (DGIs) are rare but can occur in both adults and neonates[6,12,13]. If infections are not detected and/or adequately treated, ascending infections, such as epididymitis and salpingitis, can result in a variety of serious complications and sequelae, particularly in women who bear the major burden of disease; these complications and sequelae include pelvic inflammatory disease (PID), chronic pelvic pain, ectopic pregnancy and infertility. Gonorrhoea also facilitates the transmission and acquisition of other STIs including HIV infection. Gonococcal infections can lead to complications during pregnancy, and infected women can also transmit infections to children during birth causing ophthalmia neonatorum, which was a leading cause of blindness in the pre-antimicrobial era. Conjunctivitis in adults is also observed sporadically. Thus, gonorrhoea causes substantial morbidity and socioeconomic consequences globally[12,14,15].

In the absence of a gonococcal vaccine, management and control rely on effective, affordable and accessible antimicrobial treatment, supported by adequate prevention, diagnostic testing or screening, notification and management of sex partners of infected individuals, and epidemiological surveillance. However, *N. gonorrhoeae* has developed or acquired antimicrobial resistance (AMR) to all antimicrobials recommended earlier as first-line or second-line empirical treatment of gonorrhoea (for example, sulfonamides, penicillins, tetracyclines, fluoroquinolones, early-generation macrolides, such as erythromycin, and cephalosporins, such as cefuroxime). This extensive resistance has been accomplished by an accumulation of AMR determinants, most of which do not seem to substantially reduce the biological fitness of the bacterium[16–21] (FIG. 1). This AMR is of serious public health concern as the pathogen has become highly resistant to all previously recommended antimicrobials, and resistance to the currently recommended extended-spectrum cephalosporin (ESC) ceftriaxone and macrolide azithromycin has also emerged. On the basis of the high global prevalence of gonorrhoea, the high level of antimicrobial use and/or misuse, suboptimal diagnosis, limited control and surveillance of AMR, suboptimal or slow update of management guidelines, and the extraordinary ability of *N. gonorrhoeae* to acquire or develop — and retain — AMR, it is likely that the global impact of gonorrhoea, including its severe complications and sequelae, will increase, and further *N. gonorrhoeae* AMR will evolve in the future. Consequently, improved global actions and research efforts to retain gonorrhoea as a readily treatable infection are essential.

This Primer focuses on the epidemiology, aetiological agent, pathogenic mechanisms/pathophysiology, diagnosis, screening, prevention and management of gonorrhoea. We also discuss global actions and research efforts imperative for future management and control of gonorrhoea.

Epidemiology

In 2016, the WHO estimated that there were 86.9 (95% uncertainty interval 58.6–123.4) million incident global cases of gonorrhoea (global prevalence 0.9%) among adults 15–49 years of age[22] (FIG. 2). The epidemiological diversity of gonorrhoea manifests itself in the variability of the geographical distribution and the prevalence among certain populations; determinants of such variability include sexuality and sexual orientation, socioeconomics, demographics, geographical and cultural ramifications (including stigma and taboos), and access to and quality of sex education, prevention, testing and diagnostics, as well as political commitment in the provision of health services[23–25].

Epidemiological determinants

When individual countries, especially in industrialized settings, embarked on prevention and care of STIs on the basis of the established determinants of STIs, declines in rates of gonococcal infections were observed during the late 1980s. However, this decline was short-lived, as increases in gonococcal infections rates have been reported since the late 1990s. Observations have identified a number of factors, both established and new, as important to explain the high rates of STIs, including gonococcal infections; these factors include ethnic background, sexuality and sexual preferences, sexual mixing patterns, such as assortative mixing by race and/or ethnicity (that is, the tendency to connect with individuals of the same race and/or ethnicity) and disassortative mixing by risk group (that is, the tendency to connect with individuals with a different risk level), gender and disparities in economic status and access to services, as well as the intrinsic characteristics of the pathogen[24,26–30].

Other reasons for the recent increase in gonorrhoea incidence in many high-resourced settings include changes in sexual behaviour in the era of antiretroviral treatment for HIV infection (that is, because of the availability of antiretroviral treatment and the perception that HIV infection is no longer life-threatening in the short term, people are less cautious and have sex

with new and casual partners without using condoms), increased electronic connectivity (for example, the use of dating apps for meeting sex partners), increased number of casual unknown partners, larger sexual networks, increased travel and variable access to services[30,31]. Another factor to be taken into consideration is the increasing use of drugs in sexual networks, particularly common among MSM and female sex workers. Finally, certain key populations are at higher risk of and disproportionately affected by STIs, including gonorrhoea; such populations include MSM, migrants, young people and sex workers.

Incidence and prevalence

The aforementioned factors, mostly in combination, probably substantially contributed to the varying increases in gonorrhoea case rates in the past 5–10 years, even in countries with more comprehensive health systems. For example, in the USA and in the European Union/European Economic Area (EU/EEA), both socioeconomic status and ethnic background have been observed to highly correlate with gonococcal infection rates. In the USA in 2017, the rate of reported cases of gonorrhoea was approximately eight times higher among black populations than among white populations.



Fig. 1 | **Recommended empirical therapy for gonorrhoea and emergence of AMR in *Neisseria gonorrhoeae*.** Each bar represents a gonorrhoea therapy, and the length of the bar represents the time period from when the therapy started to be used until when clinical and/or in vitro resistance threatening the effectiveness of that specific antimicrobial therapy emerged. In vitro verified antimicrobial resistance (AMR) determinants are also shown[16–21,218–220]. PBP2 amino acid alterations that increase the minimum inhibitory concentration (MIC) of extended-spectrum cephalosporins (ESCs; verified, for example, by site-directed mutagenesis or transformation) in nonmosaic and mosaic (in which concomitant epistatic mosaic *penA* mutations are also needed) *penA* alleles are noted by an asterisk[218–220]. Additionally, PBP2 G542S, P551S, and P551L amino acid alterations in nonmosaic *penA* alleles have been statistically associated with gonococcal strains with decreased susceptibility to ESCs[221–223]. A grave concern is that during the past decade(s) resistance to azithromycin and decreased susceptibility to the ESC ceftriaxone, the last remaining option for empirical monotherapy, have been reported worldwide. The first *Neisseria gonorrhoeae* strain with high-level resistance to ceftriaxone was isolated in 2009 in Japan, which was followed by some isolates with high-level ceftriaxone resistance in 2011 in France and Spain. During subsequent years, ceftriaxone-resistant isolates have been characterized in many countries including Japan, China, Australia, Singapore, Canada, Argentina and several European countries. Furthermore, treatment failures with ceftriaxone were verified in Japan, Australia and in several European countries[15,16,153,224–240]. In 2014, the first failure of ceftriaxone–azithromycin dual therapy for gonorrhoea was verified in the UK[241]. Worryingly, since 2015, an international spread of one ceftriaxone-resistant gonococcal strain, initially described in Japan, has been confirmed[229–235,239,240,242,243], and the first strain with resistance to ceftriaxone plus high-level azithromycin resistance was isolated in 2018 in the UK and Australia[236–238]. rRNA, ribosomal RNA; SNP, single-nucleotide polymorphism.



Fig. 2 | **Estimated new global cases of gonorrhoea in 2016.** Estimated numbers (in millions) of incident cases of gonorrhoea in adults (15–49 years of age) by WHO region[22]. These data correspond to 20 new gonococcal infections per 1,000 women and 26 per 1,000 men globally. The highest incidence was in the WHO African region, with 41 cases per 1,000 women and 50 per 1,000 men, followed by the WHO region of the Americas, with 23 cases per 1,000 women and 32 per 1,000 men; the lowest incidence was in the WHO European region, with 7 cases per 1,000 women and 11 per 1,000 men[22]. The World Bank Income Classification is also shown. Data from REF.[22].

Higher rates were also noted among American Indians and Alaskan Natives, Native Hawaiians and individuals with Hispanic heritage, whereas the rate among individuals with Asian heritage was half the rate among white individuals[30,31]. In the USA, the number of gonorrhoea cases increased by 67% from 2013 (n = 333,510) to 2017 (n = 556,413)[32]. The proportion of gonococcal isolates cultured from MSM increased from 3.9% in 1989 to a high of 38.5% in 2017, reflecting epidemiological changes and possibly changes in the health care-seeking behaviour of men with gonorrhoea as well as improved reporting of sexual orientation in the USA[30,31].

In the EU/EEA, the number of reported gonorrhoea cases has increased by >200% since 2008, from 29,434 cases in 2008 (with an incidence of 7.85 per 100,000 population) to 89,239 cases in 2017, with the highest numbers of cases in the UK, France, the Netherlands and Spain[33]. Of note, higher prevalence in these countries might be in part accounted for by the availability of comprehensive sexual health systems, frequent testing and/or surveillance. The highest incidence of gonorrhoea in the EU/EEA is in young adults (15–24 years of age)[33]. MSM accounted for ~25–30% of all the cases in the EU/EEA during recent years — 30% of the reported gonorrhoea cases (57% of the cases reporting sexual orientation) in Europe in 2017 (REF.[33]); however, over the past decade, substantial increases also occurred among heterosexual men, men with no sexual orientation reported and women. In the UK, MSM experienced substantial increases in reported STIs in 2017. Of the 50,032 new nonviral STI diagnoses in MSM in 2017, 43% were gonococcal infections and, between 2016 and 2017, gonococcal infection diagnoses increased by 21%[34].

The geographical setting in which people live also seems to have a role in the prevalence of gonococcal infection, probably reflecting differences in the access to information regarding STIs, availability, accessibility and quality of health-care services, and social factors such as the effect of stigma on health-care-seeking behaviours. Observations showed that the prevalence of gonorrhoea in women aged 15–24 years in clinical or community settings in South Africa was ~4.6%, whereas in southern Africa and eastern Africa the prevalence was 1.7%. Furthermore, in the same study, the prevalence in a high-risk population in eastern Africa, mostly sex workers, was 8.2%[35].

In low-income settings, syndromic management of STIs is mainly performed, and no comprehensive

aetiology-based surveillance systems enable accurate assessment nationwide of increases or decreases in gonorrhoea prevalence in the general population or in subpopulations. However, even in many high-income settings, for example in Europe, the surveillance data should be interpreted with caution as the surveillance systems, testing, methodologies and quality assurance are not standardized across countries and remain weak in several settings[33,36]. Finally, whole-genome sequencing (WGS) will revolutionize our understanding of the epidemiology of gonorrhoea and the geographical and temporal spread of AMR and antimicrobial susceptible *N. gonorrhoeae* strains in different populations and subpopulations, including at-risk groups (see Outlook, below).

Gonorrhoea in MSM on pre-exposure prophylaxis. Another topical area of interest is the observation of rapid increases in the incidence of gonorrhoea, and other STIs, in high-resourced settings among MSM taking pre-exposure prophylaxis (PrEP) for the prevention of HIV infection. Some published data reported that MSM using PrEP can be ~25 times more likely to acquire a gonococcal infection than MSM not using PrEP[37]. A multisite open-label study of just under 3,000 gay and bisexual men using PrEP, conducted in Australia between 2016 and 2018, showed a significant increase in the incidence of STIs (including gonorrhoea, *Chlamydia trachomatis* infection and syphilis) during a follow-up period of 1.1 years. Younger age, greater number of sex partners and group sex participation were associated with a greater risk for an STI, whereas inconsistent or no condom use with casual partners was not[38]. A systematic review commissioned by the WHO in 2018–2019 identified 88 STI studies, primarily in MSM in high-income countries, which found that STI prevalence was high in people prior to starting PrEP, and STI incidence varied by setting and population included in the review. However, pooled STI incidence generally remained high during follow-up when taking PrEP[39,40]. However, notably, individuals on PrEP are monitored more closely and tested more frequently for STIs than non-PrEP users. When both populations were controlled for frequent monitoring, as in the PROUD study, no statistically significant differences in STI rates were found between men taking PrEP and the control group[41]. Thus, it would seem that the reduced risk for and fear of HIV infection has led some PrEP users, especially young MSM, to reduce condom use and/or increase other risky sexual behaviours and, therefore, to place themselves at increased exposure to other STIs, including gonorrhoea. However, given the conflicting conclusions from different population studies on this point, more observations and studies are needed to identify the factors behind these contradictory conclusions, as well as to detail the risk factors and elements that may be responsible for the findings of increased STI risk in some populations and to better understand the ideal monitoring and screening intervals of individuals taking PrEP.

Box 1 | **Models to study *Neisseria gonorrhoeae* pathogenesis**

Much of the information concerning *Neisseria gonorrhoeae* pathogenesis has come from studying the physiological and genetic properties of the organism, including determination of growth and nutrient requirements and surface-exposed molecules, with in vitro bacterial cultures. However, these experimental conditions do not always mirror in vivo conditions and, therefore, cell culture models can be useful to learn about the interactions between the bacterium and the host, particularly how *N. gonorrhoeae* attaches to and is internalized into eukaryotic cells. These studies have mainly used immortalized transformed human cell lines, but have occasionally used newly harvested human primary cells[1], as cell lines do not always replicate the properties of tissues. Primary cultures are difficult to isolate and maintain and are considerably heterogeneous, whereas tissue explants enable the study of the interactions of the organism with different cell types in a complex tissue. Compared with other primary tissues, fallopian tube tissue is relatively easy to obtain from hysterectomies and is a clinically relevant tissue environment[70], particularly for modelling pelvic inflammatory disease[212].

Animal models are useful to study colonization, growth and immune response in a host. Of note, because *N. gonorrhoeae* is restricted to the human host, the bacterial proteins have evolved highly specific interactions with human molecules, rendering early mouse models of limited value. Despite this limitation, female mice treated with 17β-oestradiol (to promote prolonged colonization and/or infection) have become a standard in the field[193]. Transgenic mouse models expressing human receptors for *N. gonorrhoeae* are in development and will have greater utility in the future[194,195], although no existing mouse model totally mimics a natural human infection. In the 1960s, primate models were examined and chimpanzees reportedly developed symptomatic gonorrhoea[213], but chimpanzees are no longer used for biomedical research in the USA and rarely elsewhere, although new primate models might be developed in the future. The human challenge model is the most relevant existing model[214]. Only men can participate, as they have a lower risk of complications from infection than women. This model has only been used to investigate initial colonization determinants, and its utility is limited owing to small cohorts per study, the requirement for treatment as soon as symptoms develop and being only applicable to men.

Mechanisms/pathophysiology

The bacterium N. gonorrhoeae

Growth and metabolism. *N. gonorrhoeae* is a fastidious organism that is sensitive to many environmental factors such as oxygen, nonphysiological temperatures, desiccation and the presence of toxic substances (such as many fatty acids), among others[42]; thus, the bacterium does not survive for long outside the human host, and is difficult to culture (BOX 1). Many strains have incomplete biosynthetic capabilities for amino acids, presumably because amino acids and other important nutrients are readily obtained from the human host. Iron (which is essential for bacterial growth) is acquired from the host by binding iron-containing host proteins such as transferrin, lactoferrin and haemoglobin at the bacterial surface and stripping these molecules of iron that is then delivered to the bacterial cytoplasm[43]. Owing to the broad range of oxygen levels within different niches of the male and female urogenital tracts, it is possible that *N. gonorrhoeae* encounters aerobic, microaerobic, and anaerobic conditions within the host, and the bacteria are able to grow in all these conditions[44].

Genetics. Using WGS, it has been shown that the modern gonococcal population is not as old as previously thought and has been shaped by antimicrobial treatment of STIs as well as other infections, leading to the emergence of two major genomic lineages, one multidrug-resistant and one multidrug-susceptible, with different evolutionary strategies[45]. *N. gonorrhoeae* has a single circular chromosome between ~2.1 and 2.3 megabase pairs (~2,200–2,500 protein-coding sequences), which exists as diploid, homozygous, chromosomes[46,47].

In addition, *N. gonorrhoeae* can acquire additional DNA via horizontal genetic transfer (HGT), the noninherited external acquisition of new genetic material from another bacterium. HGT occurs mainly by type IV pilus-mediated DNA transformation (uptake of DNA from the environment and subsequent incorporation into the genome). *N. gonorrhoeae* is naturally competent for transformation during its entire life cycle, but transformation only occurs at high frequency between cells of *N. gonorrhoeae* and other *Neisseria* species. Approximately 80% of isolates carry a chromosomal insertion called the gonococcal genetic island, which has genes similar to those carried on the conjugal plasmid (that is, genes involved in conjugation — the DNA transfer between bacteria by cell-to-cell contact). However, in *N. gonorrhoeae* these conjugation gene products act to secrete chromosomal DNA into the medium that is then available for DNA transformation. Pilus-mediated DNA transformation provides efficient transport of DNA into the bacterial cell and DNA uptake sequences are highly represented in *Neisseria* genomes (~1,900–2,000 copies per genome)[48,49]. This efficient transformation is one reason why AMR determinants efficiently spread from cell to cell. Notably, this ability of *N. gonorrhoeae* to transfer DNA between strains makes clonal analysis difficult because alleles are not stably linked and led to the creation of the multilocus sequence typing system to characterize bacterial lineages by the DNA sequence type of several defined and more conserved housekeeping genes[50]. Multilocus sequence typing systems are now available for many different bacterial species[51]. Furthermore, this reassortment of alleles suggests that mixed-strain gonorrhoea infections are common[52,53], although widely unrecognized, as most clinical laboratories analyse and save single colonies when culturing isolates, probably underestimating the incidence of mixed infections. Ideally, multiple colonies should be tested.

Nearly all gonococcal strains contain a cryptic plasmid (with no defined functions); many contain a plasmid encoding a penicillinase (mostly TEM-1 or TEM-135 β-lactamase), which results in high-level penicillin resistance, and conjugative plasmids, which sometimes carry *tetM* causing high-level tetracycline resistance, although these plasmids are not as prevalent as reported for many other bacterial species[16,54]. Several penicillinase-encoding plasmids of different size have been described in *N. gonorrhoeae* and named according to their epidemiological origin, such as the widely spread and most common African, Asian and Rio/Toronto plasmids. Different conjugative gonococcal plasmids carrying *tetM* have also been described, the most common being the American *tetM* plasmid and the Dutch *tetM* plasmid[16,54]. In addition, several double-stranded and single-stranded bacteriophage gene islands have been annotated within the *N. gonorrhoeae* genome, but no isolated bacteriophage that can infect and lyse the bacteria has been found[55].

Colonization determinants. *N. gonorrhoeae* shares many colonization determinants with other human-restricted *Neisseria* species that rarely cause infection. The factors required to establish a host niche include the type IV pilus, the opacity protein family (Opa proteins), the porin PorB, efflux pumps and metal transport systems (FIG. 3). *N. gonorrhoeae* probably has to compete with the resident microbiota for colonization, but little is known about how different resident commensal organisms may limit or cooperate with *N. gonorrhoeae* during colonization.

Gonococcal pili are required for efficient mucosal colonization (typically of nonciliated columnar epithelia) and carry out many functions, including initial adherence to host cells and tissues, self-adherence and adherence to other *N. gonorrhoeae* cells, a means to crawl along mucosal surfaces called twitching motility, protection from PMNL killing mechanisms[56], and HGT by DNA transformation[57]. Clinical isolates of *N. gonorrhoeae* are always piliated, but quickly lose pilus expression in laboratory culture through a variety of mechanisms, showing that pilus expression is under strong selective pressure during infection.

The Opa proteins mainly act as adhesins that bind to a variety of receptors found on many different cells and tissues[58] and mediate more intimate attachment and initiation of microcolony formation. Most Opa proteins bind to one or more human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), a family of surface-exposed proteins. Opa proteins only bind to human forms of these proteins, and a few Opa proteins also bind to heparan sulfate proteoglycans. Although some Opa–CEACAM interactions lead to cell signalling events, such as induction of the oxidative burst from PMNLs, most Opa interactions seem to be important for adherence to cells and tissues[59].

All Gram-negative bacterial porins (transmembrane channel proteins) act to allow small molecules access to the periplasm. The *N. gonorrhoeae* porin (PorB) is one of the most abundant proteins in the outer membrane; it increases attachment, is then translocated to the host cell mitochondria and impairs the ability of phagocytes to kill the bacteria. Other important properties include resisting the action of complement factors, modulating apoptosis, invasion of host cells and involvement in AMR[60–63].

N. gonorrhoeae expresses up to five efflux pump systems: MtrC–MtrD–MtrE, MacA–MacB–MtrE, NorM, FarA–FarB–MtrE and MtrF[64–66]. These export pumps have varying narrow or extensive substrate specificity and have many roles in pathogenesis, including removing toxic molecules encountered during infection, such as fatty acids and cationic peptides, and removing antimicrobials from the cell (that is, acting as AMR determinants). Finally, there are three iron acquisition systems in the envelope of *N. gonorrhoeae*, and each can strip iron from a human protein that is designed to sequester iron from pathogenic organisms. There is an acquisition system for transferrin (TbpA–TbpB), one for lactoferrin (LbpA–LbpB) and one for haeme (HpuA–HpuB), which can be found, for example, in haemoglobin[43].

Infection dynamics

All bacteria that live in or on people need to colonize and grow, whether they are commensal organisms that rarely cause harm or frank pathogens. The pathogenesis field defines colonization and growth determinants as



Fig. 3 | ***N. gonorrhoeae* cell envelope structure.** *Neisseria gonorrhoeae* is a Gram-negative bacterium, frequently encountered as diplococci (individual cells are ~0.6–1 μm in diameter), with a characteristic cell envelope consisting of a cytoplasma membrane (the inner membrane), a periplasmic space containing the peptidoglycan cell wall[244] and the outer membrane containing lipo-oligosaccharide (LOS), which is similar to lipopolysaccharide (LPS) of other Gram-negative bacteria, except it does not have the polymeric O-antigen characteristic of LPS. The type IV pilus is a long, thin fibre that reaches far outside of the cell envelope, mainly composed of many copies of one protein, pilin. Type IV pilus assembly requires a complex molecular machine, called the assembly apparatus, that sits within the cell envelope to produce the fibre on the outside of the cell[245]. The pilus is a dynamic structure that can be retracted by the assembly apparatus, which generates one of the largest physical forces on record by a biological machine[246]. The Opa proteins are a family of integral outer membrane proteins whose expression is stochastically controlled[247]. Each *N. gonorrhoeae* isolate carries ~11 *opa* genes, and expression of each is controlled by independent molecular events that turn on or off the expression of each *opa* gene. A single bacterial cell may express none of the Opa proteins, a single Opa, or a combination of several. There is a correlation between patterns of Opa expression and bacteria isolated from females during menses[248], and increased numbers of Opa proteins are expressed during human volunteer infections[249]. The outer-membrane-localized porin (PorB) allows small molecules to enter the periplasm and the reduction modifiable protein (Rmp) is associated with PorB and elicits antibodies that block the binding of anti-PorB antibodies[250]. The five efflux pump systems (FarA–FarB–MtrE, NorM, MtrC–MtrD–MtrE, MacA–MacB–MtrE and MtrF) have varying substrate specificity and many roles in pathogenesis, including removing toxic molecules encountered during infection and exporting antimicrobials (acting as resistance determinants). The three iron-scavenging complexes (LpbA–LpbB, HpuA–HpuB and TbpA–TbpB) are required to obtain iron from the host. Adapted from REF.[5], Springer Nature Limited.

virulence determinants even though they are often found also within organisms that do not cause overt pathology. However, for a pathogenic organism to do damage, it usually needs to colonize specific anatomical sites and grow (except when pathogenesis occurs through production of a toxin away from the site of infection).

Transmission. *N. gonorrhoeae* infects the mucosal epithelium of the male and female urogenital tracts, the rectum, pharynx or conjunctiva[12]. *N. gonorrhoeae* is mainly transmitted through unprotected vaginal, anal or oral intercourse. During vaginal sex, transmission rates from men to women are higher than from women to men[67]. Ejaculate from infected men contains millions of bacteria, effectively injecting the organism into the receiving anatomical site. How the organism is effectively transmitted from vaginal, rectal or oral/pharyngeal locations to the male urethra is not completely understood. Of note, *N. gonorrhoeae* infection amplifies the risk for acquisition and transmission of HIV and several other STIs[68,69]; all the underlying mechanisms are not completely understood, but probably involve factors such as inflammation, destruction of the mucosa and discharges. Furthermore, women with *N. gonorrhoeae* infection can effectively transmit the infection to their children during birth (intrapartum), but not during pregnancy; the neonate's conjunctiva is highly exposed during transit of the birth canal, and *N. gonorrhoeae* infection of the conjunctiva results in ophthalmia neonatorum.

Host defences against infection act at many levels. *N. gonorrhoeae* has no ability to persist on or to penetrate the skin, and it requires a mucous membrane for colonization. Many barriers in mammalian cells limit transit of organisms into the body, including the ciliary action of some epithelia. Peptidoglycan fragments and lipo-oligosaccharide (LOS) released by *N. gonorrhoeae* can disrupt the ciliary action of the epithelium and may promote colonization[70,71]. Once colonization is established, innate and adaptive immune responses act to block or limit the growth of an organism. However, as a host-restricted organism that has co-evolved with its human host, *N. gonorrhoeae* has intricate mechanisms to limit the action of these host defence systems.

Innate immune systems. Resident tissue macrophages are one of the first cells that *N. gonorrhoeae* encounters during infection[72] (FIG. 4). Whether macrophages have a role in limiting *N. gonorrhoeae* infection is not clear, but macrophages, dendritic cells and epithelial cells may all be responsible for producing the chemokines



Fig. 4 | ***N. gonorrhoeae* infection.** Initial adhesion of *Neisseria gonorrhoeae* to the epithelium requires type IV pili and, then, Opa proteins for more intimate adhesion. The bacteria can then proliferate on the epithelial surface and invade underlying tissues via transcytosis. *N. gonorrhoeae* also releases peptidoglycan fragments, outer membrane vesicles (OMVs) and lipo-oligosaccharide (LOS), thereby activating Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-containing protein signalling in tissue-resident dendritic cells and macrophages. In response to bacterial stimulation, these cells produce chemokines and cytokines (for example, IL-1, IL-6, IL-8, IL-17 and tumour necrosis factor (TNF)) that can recruit polymorphonuclear leukocytes (PMNLs); however, the bacteria can often survive phagocytosis, antibacterial factors released during degranulation or NETosis (that is, cell death mediated by neutrophil extracellular traps (NETs)). *N. gonorrhoeae* has many ways to prevent complement killing by the membrane attack complex; for example, the LOS can be modified by sialic acid, when the precursor substrate, CMP-NANA, is supplied by the host, to enhance complement resistance[251]. Sialylated LOS binds C3b and promotes its inactivation to iC3b via factor I, whereas the outer-membrane-localized porin (PorB) binds factor H and C4BP, thereby hiding the bacteria from complement recognition. When complement activity is inhibited (for example, by mutation or owing to immune suppressive treatment), systemic *N. gonorrhoeae* infections are prevalent. Whether the resistance to complement is also important in localized sites of colonization is not known. C4BP, C4b-binding protein; NLR, nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor. Adapted from REF.[5], Springer Nature Limited.

and cytokines induced during infection. Some of these host effectors are responsible for inducing the massive PMNL response that manifests as the purulent exudate characteristic of symptomatic urethral gonorrhoea. *N. gonorrhoeae* can survive the various antimicrobial functions of PMNLs including phagocytosis, the release of reactive oxygen species, cationic peptides and antimicrobial enzymes, metal sequestration and PMNL extracellular traps[73]. *N. gonorrhoeae* can also modulate the apoptosis of epithelial cells, macrophages, T cells and PMNLs, but as both the inhibition and enhancement of apoptosis has been reported, the relevance of apoptosis modulation to infection remains controversial[74,75]. In addition, the role of PMNLs during *N. gonorrhoeae* infection also remains controversial. PMNLs probably influence infection by killing some of the bacteria but enabling the spread of others[73].

The classical and alternative complement pathways act to kill many organisms, and *N. gonorrhoeae* has evolved ways to avoid both pathways during uncomplicated infections[76]. Indicative of its extreme host restriction and evolution, *N. gonorrhoeae* remains sensitive to animal complement system components[61]. *N. gonorrhoeae* uses several mechanisms to limit complement-mediated killing by blocking deposition or activity of several complement factors[61] (FIG. 4). People with complement deficiencies are at increased risk of DGI, showing that the complement system helps to limit gonococcal survival in the blood stream[77]. Increased incidence of DGI and other disseminated *Neisseria* spp. infections was observed when patients were treated with eculizumab, a complement inhibitor, but this study did not report altered rates of uncomplicated gonorrhoea[78]. Whether complement effectively functions at mucosal sites of colonization is not fully known.

Adaptive immunity. As an organism that has co-evolved with its sole host for centuries, and possibly throughout all recorded time, the colonization determinants of *N. gonorrhoeae* are exquisitely adapted to life within humans. By contrast, the human adapted immune system has variable components (B cells and T cells) that can change to limit infection. *N. gonorrhoeae* is generally thought to be immunosuppressive[79], although there are suggestions that any immunosuppression is incomplete. Many studies show that antigonococcal antibodies are found in people with active or previous infection, demonstrating a humoral immune response[80]. In addition, the existence of three, independent, antigenically variable surface antigens (type IV pilus, Opa proteins and LOS) also provides evidence that there are potentially protective responses directed against these antigens that necessitate the complex variations[81]. These antigens can all vary during infection and colonization; for example, the surface-exposed antigenic epitopes of pili will vary and pilus expression can be lost, the number and type of expressed Opa proteins will vary (FIG. 3), and the type of sugars on the LOS molecule can change. Although some of this surface variation alters some functional properties of *N. gonorrhoeae*, the most important function of antigenic variation is immune avoidance, which enables reinfection presumably even with the same gonococcal strain, as protective immunity to *N. gonorrhoeae* capable of preventing subsequent infections has never been recorded. Extensive surface molecule variation by *N. gonorrhoeae* also prevents these molecules from being considered viable vaccine candidates. A more detailed examination of immune suppression and responses during human infection is needed.

Host damage. *N. gonorrhoeae* is not a very disruptive pathogen, as it is well adapted to its human host and rarely lethal. It does not produce any exotoxins that can destroy host cells, but does secrete peptidoglycan fragments, outer membrane vesicles (OMVs) and LOS that are toxic to mammalian cells and can specifically inhibit the ciliated cells on fallopian tube tissues[70,71]. Moreover, when PMNLs are recruited to sites of infection, PMNL antimicrobial products are released that can damage the tissue. All of these factors contribute to the damage and scarring of the fallopian tube tissue that is characteristic of PID. These factors can also cause damage at other sites of infection, particularly during DGIs in which, in addition to fever, dermatitis, infectious arthritis and (less frequently) septicaemia, endocarditis and meningitis can occur.

Table 1 | **Tests for the diagnosis of *Neisseria gonorrhoeae***

Parameter		Microscopy	Culture	NAAT
Specimen types[a]				
Urine	Female	No	No	Yes[b]
	Male	No	No	Yes
Urethral swab		Yes	Yes	Yes
Rectal swab		No	Yes	Yes/no[c]
Pharyngeal swab		No	Yes	Yes/no[c]
Conjunctival swab		Yes	Yes	Yes/no[c]
Performance				
Sensitivity[d]		Low–high	Moderate–high	Very high
Specificity[d]		Moderate–high	Very high	Moderate–very high
Cost		Low	Moderate	Moderate–very high
Instrumentation		Microscope	Routine microbiology	Moderate–large footprint
Technical complexity		Low–moderate	Moderate	Low–high
Level of laboratory infrastructure		Low	Low–intermediate	Intermediate–high
Potential as a POCT		Yes	No	Yes

NAAT, nucleic acid amplification test; POCT, point-of-care test. [a]Yes or no indicates appropriateness of specimen type. [b]The sensitivity is substantially lower than in other approved specimen types and a negative result does not exclude gonococcal infection. [c]Yes/no indicates that not all platforms have received FDA approval for that specific specimen. [d]Can highly depend on specimen type. Adapted from Unemo, M. & Ison, C. in *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (eds Unemo, M. et al.) 21–54 (World Health Organization, 2013)[85].

Diagnosis, screening and prevention

Clinical presentation and diagnosis

The incubation period for urogenital gonorrhoea ranges from ~2 days to 8 days[82]. The clinical manifestations of gonorrhoea are variable and differ markedly in men and women[12]. At least 90% of men with gonococcal urethritis are symptomatic, presenting with obvious urethral discharge and dysuria, a fact that permits the application of syndromic diagnosis (based on a set of symptoms and signs that are characteristic of a clinical manifestation) in many settings as both a time-saving and cost-saving measure. For men with symptomatic urethritis, Gram stain may be used to support symptom evaluation. By contrast, laboratory-based diagnostic tests have a more important role for gonococcal detection in asymptomatic men, women and in patients of all genders for extragenital (rectal and pharyngeal) infections, which are mostly asymptomatic or present with nonspecific symptoms. Although ~40% of women with gonococcal cervicitis may report abnormal vaginal discharge, this symptom is unreliable for syndromic diagnosis of gonorrhoea, as many other equally or more common genitourinary infections in women (for example, bacterial vaginosis, trichomoniasis and vaginal candidiasis) may cause the same symptoms.

Microbiological diagnosis of gonorrhoea can be challenging, as many regions do not have a laboratory-based diagnostic capability and rely on syndromic management algorithms to guide empirical antimicrobial treatments[14]. Microbiological diagnosis is performed by the detection of Gram-negative diplococci in stained smears using microscopy, culture of *N. gonorrhoeae* and/or nucleic acid amplification tests (NAATs) detecting *N. gonorrhoeae* DNA or RNA.

Traditional diagnostic methods

Microscopy. In resource-limited settings, light microscopy of Gram-stained samples is often the only method available to diagnose infection with *N. gonorrhoeae* presumptively (TABLE 1). The sensitivity and specificity of the Gram stain, which tests for the presence of characteristic Gram-negative diplococci within PMNLs, can vary substantially between studies and depends upon the specimen;

the highest sensitivity and specificity were reported with urethral swab samples from symptomatic males (89% to >98% and >95%, respectively)[6,13,83–85], whereas the sensitivity was as low as 40–50% in urethral specimens from asymptomatic males, and in endocervical or urethral specimens from women[13,83,84]. This difference can probably be explained by a reduced bacterial load, particularly in these urethral samples, and by the presence of many other bacterial species in the endocervical samples. Gram stain is not suitable for the diagnosis of *N. gonorrhoeae* from pharyngeal specimens (because other *Neisseria* species with similar morphology are prevalent in the oral and nasopharyngeal cavity) or rectal specimens (which have a sensitivity ≤40%)[82–84]. A methylene blue staining method is an alternative to the Gram stain, and similar high sensitivity and specificity were reported for diagnosing gonococcal urethritis in men[86].

Culture. Prior to the introduction of NAATs, culture (TABLE 1) of the organism was the gold standard and this remains the only diagnostic method available in some settings as it is a low-cost method. Culture also remains recommended for test-of-cure for treatment failure, in cases of sexual abuse and to evaluate PID[13,85,87]. Furthermore, complete AMR testing can only be accomplished if *N. gonorrhoeae* is cultured[83,85,87,88]. Culture performance is dependent upon factors such as anatomical site of the cultured sample, method of specimen collection, media and conditions used to transport the sample to the diagnostic centre[83,87,89], nonselective and/or selective culture media[84,85,89,90], conditions of incubation[82,85] and species confirmatory tests. Cultures obtained too soon after exposure (<48 h) may give false-negative results[13], and a repeated culture sample some weeks later is sometimes considered. Culture of urogenital specimens usually has a sensitivity ranging from 72% to 95%, but can have a sensitivity of 95–100% in settings with extensive experience in appropriate specimen handling and culture[83,84]. However, the sensitivity of culturing pharyngeal and rectal specimens is much lower.

Presumptive identification of cultured *N. gonorrhoeae* isolates is frequently accomplished by typical colony appearance on selective media, Gram-stained microscopy and the oxidase test, which detects the presence of cytochrome oxidase[82,84,85]. For definitive *N. gonorrhoeae* identification, immunological tests frequently targeting PorB[85,91–93], sugar utilization tests or other biochemical tests[6,85,91,94], NAATs or mass spectrometry (that is, matrix-associated laser desorption ionization time of flight (MALDI-TOF mass spectrometry))[6,95–97] are frequently performed. These tests differentiate *N. gonorrhoeae* from species such as *N. meningitidis*, *Neisseria lactamica*, *Neisseria cinerea, Neisseria subflava* or other genera that may occasionally grow on even the selective culture media and may be present particularly in the pharynx but also at other sites[85]. Finally, DNA extraction from cultured isolates is also currently the best method to obtain DNA for genomic analysis, as clinical specimens often either do not contain sufficient concentrations of DNA, or contain too much DNA from other bacterial species or human cells. Furthermore, methods for genomic DNA purification from clinical specimens have not been sufficiently developed or standardized[98].

NAATs

NAATs are currently recommended for gonorrhoea diagnosis in most high-income countries[13,82,87,99]. NAATs are now the preferred diagnostic test because specimen collection is noninvasive (urine or self-collected particularly vaginal swabs); viable organisms are not required for detection, permitting less stringent transportation and storage methods[85,100]; most have superior sensitivity with maintained high specificity (which vary between NAATs and anatomical site tested) compared with culture; they produce more rapid results (many later generation NAAT platforms allow for high throughput and automation); and many can simultaneously detect other STI-associated pathogens (particularly *C. trachomatis*)[13,85,87,101]. Initially, a number of in-house, PCR-based NAATs were used locally and continue to be used as confirmatory tests or for diagnosis in resource-limited settings[93,102–104]. In-house NAATs generally target conserved regions of genes such as the *porA* pseudogene, *opa* genes, *gyrA* (encoding DNA gyrase subunit A), *cppB* (encoding cryptic plasmid protein B) and the methyltransferase genes of *N. gonorrhoeae*[102]. Few reports have compared the performance of such in-house NAATs with culture or commercially available NAATs[102]. In high-income countries, in-house NAATs have largely been replaced with commercial NAATs that have been comprehensively validated and received regulatory approval from the US FDA[13,87,101] (TABLE 2).

In 2019, the first two NAATs (Aptima Combo 2 assay and Xpert CT/NG) for gonococcal detection received FDA approval also for extragenital specimens such as rectal and pharyngeal infection[105], and licensing for additional NAATs is in progress. Several studies indicate that many additional NAATs are more sensitive, with maintained high specificity, than culture for diagnosing *N. gonorrhoeae* from pharyngeal and rectal specimens (TABLE 2); however, such tests should be used only after rigorous local performance evaluations[82,87,106], and additionally a confirmatory NAAT with a different target should be used for such specimens[82,85,87,100], as other *Neisseria* species, which can be frequently present especially in the pharynx, could be misidentified as *N. gonorrhoeae*[87,100]. Thus, when using NAATs to detect *N. gonorrhoeae*, it is important to choose the test or the testing strategy so that the positive predictive value (which is calculated based on the sensitivity and specificity of the test and on the local prevalence of the pathogen, and the last two parameters substantially affect the positive predictive value) is >90%[82,85].

The introduction of NAATs for *N. gonorrhoeae* has substantially reduced the number of cultured patient samples. FDA-approved NAATs are more expensive than culture-based methods, and are mostly used in high-income countries[13,82,87,99]. Pooling specimens (that is, combining up to 5–10 specimens and then retesting them separately if the pool is positive to ascertain which specimen(s) was positive) may reduce cost, especially in settings with high-volume testing and with low positivity

Table 2 | **FDA-approved and CE-IVD-approved NAATs for the detection of *Neisseria gonorrhoeae***

Test, instrument (manufacturer)	Gonococcal target(s)	Specimen type or cultured isolates	Sensitivity (%)		Specificity (%)		Refs
			Symptomatic	Asymptomatic	Symptomatic	Asymptomatic	
PCR							
RealTime CT/NG[a], m2000[b] (Abbott Molecular)	*opa*	CCVS (F)	96.8	95.7	99.9	99.4	107,252,253
		ECS (F)	87.1	91.3	99.7	100	
		FVU (F)	76.9	NA	99.8	NA	
		SCVS (F)	96.7–98	95.7	99.7–100	100	
		Urethral (M)	99.2	81.8	99.3	99.8	
		Urine (F)	93.8	87	99.7	99.6	
		Urine (M)	98.8	100	99.5	100	
		Urine (M/F)	100	NA	100	NA	
		Culture	99.5	NA	100	NA	100
Xpert CT/NG[a,c,d], GeneXpert (Cepheid)[b]	Two (NG2, NG4) highly conserved, noncontiguous unique chromosomal targets	ECS (F)	100	100	100	100	254
		Urine (F)	100	91.7	100	99.9	
		Urine (M)	97.8	100	100	99.9	
		VS (F)	100	100	99.8	99.9	
		Culture	100	NA	100	NA	187,255
Cobas 4800 CT/NG[a], Cobas 4800[b] (Roche)	DR9	FVU (F)	81.1	NA	100	NA	107,256,257
		Nongenital (F)	100	NA	100	NA	
		Nongenital (M)	100	NA	99.8	NA	
		SCVS (F)	84.6	NA	99.6	NA	
		Urine (M/F)	92.9	NA	100	NA	
		Urogenital (F)	97.5	NA	100	NA	
		Urogenital (M)	100	NA	100	NA	
		Culture	100	NA	100	NA	100
BD MAX[e], BD Max System (Becton-Dickinson)	Chromosomal DNA	ECS	96.3	94.1	99.9	100	258
		Urine (F)	100	88.9	99.9	99.5	
		Urine (M)	NA	80	NA	100	
		VS	96.3	94.1	99.8	99.9	
Strand displacement amplification							
Probe Tec ET[a], Viper XTR (Becton-Dickinson)	Pilin gene-inverting protein homologue	ECS (F)	87.5	91.3	99.6	98.9	107,252, 253,259
		FVU (F)	75.5	NA	100	NA	
		SCVS (F)	90.6–100	NA	100	NA	
		Urine (F)	76.7	85.7	95.6	96.9	
		Urine (M)	94.9	100	97	95.7	
		Urine (M/F)	95.8	NA	100	NA	
		CCRS (M)	67.5	NA	100	NA	106,260
		PS (M)	85.7	NA	100	NA	
		Rectal (M)	89.1	NA	99.8	NA	
		SCRS (M)	77.1	NA	99.3	NA	
		Culture	100	NA	88.9	NA	100

Table 2 (cont.) | **FDA-approved and CE-IVD-approved NAATs for the detection of *Neisseria gonorrhoeae***

Test, instrument (manufacturer)	Gonococcal target(s)	Specimen type or cultured isolates	Sensitivity (%)		Specificity (%)		Refs
			Symptomatic	Asymptomatic	Symptomatic	Asymptomatic	
Transcription-mediated amplification							
Aptima Combo 2[a,d], Panther[b] (Hologic (earlier Gen-Probe))	16S rRNA	CCVS (F)	93.8	95.7	99.3	99.7	107,252, 253,259
		ECS (F)	90.6	90.9	99.4	99.7	
		FVU (F)	88	NA	99.4	NA	
		SCVS (F)	96.2–100	NA	98.4–100	NA	
		Urethral (M)	99.2	81.8	99.2	99.7	
		Urine (F)	84.4	82.6	99.6	99.4	
		Urine (M)	97.9	100	99.7	99.5	
		Urine (M/F)	100	NA	100	NA	
		CCRS (M)	78.3	NA	99.8	NA	106,260
		PS (M)	100	NA	99.6	NA	
		Rectal (M)	93.5	NA	97.7	NA	
		SCRS (M)	84.3	NA	100	NA	
		Culture	100	NA	100	NA	100,261

All tests are both approved by the FDA and have a European Conformity (CE) In Vitro Diagnostic (IVD) certification, indicating compliance with health, safety and environmental protection standards for products manufactured or sold within the European Union/European Economic Area[101]. A large number of additional nucleic acid amplification tests (NAATs) (not shown) carry only a CE-IVD certification; in general, these NAATs are less stringently validated. CCRS, clinician-collected rectal swab; CCVS, clinician-collected vaginal swab; DR9, Direct Repeat Region 9; ECS, endocervical swab; F, female; FVU, first void urine; M, male; NA, not available; PS, pharyngeal swab; rRNA, ribosomal RNA; SCRS, self-collected rectal swab; SCVS, self-collected vaginal swab; VS, vaginal swab.[a]Can also detect *Chlamydia trachomatis*. [b]Fully automated. [c]Cartridge-based near-point-of-care test. [d]FDA approved for extragenital specimens such as rectal and pharyngeal infection[105]. [e]Can also detect *C. trachomatis* and *Trichomonas vaginalis*.

rate. However, strict evaluation of the performance characteristics of the NAAT in the local population is crucial before implementing any pooling strategy. Time to results, hands-on time, maintenance and consumption of reagents and consumables for automated platforms vary greatly between platforms, and these parameters influence the choice of platform[107,108]. A major disadvantage of commercial NAATs is the inability to perform AMR testing on gonococcal specimens[14,85,102,109]. In many regions, >80% of gonorrhoea cases are diagnosed by NAATs and, therefore, crucial information regarding AMR and gonococcal strain biology is lost. There are no recommended molecular tests for the prediction of antimicrobial susceptibility or resistance[102,110,111]; however, a PCR-based test that also detects ciprofloxacin susceptibility status has received the European Conformity In Vitro Diagnostic mark (TABLE 3) and several NAATs in the pipeline are also being developed to detect both *N. gonorrhoeae* and its ciprofloxacin susceptibility status[101]. This type of test could be important particularly in regions in which ciprofloxacin susceptible strains are still spreading and, therefore, ciprofloxacin could be used for treatment as a lower cost, oral alternative to ceftriaxone plus azithromycin, that is to spare the use of these antimicrobials and decrease the selective pressure for resistance. This concept has been tested clinically with success[101,112,113]. Notably, both the British Association for Sexual Health and HIV (BASHH) gonorrhoea guideline for the UK and the European gonorrhoea guideline for the WHO European region recommend the use of ciprofloxacin for treatment of anogenital and pharyngeal gonorrhoea if the gonococcal strain causing the infection is proven to be ciprofloxacin-susceptible using genetic or phenotypic resistance testing[82,114].

Point-of-care tests (POCTs)

Development of appropriate rapid point-of-care tests (POCTs) is a high priority for the diagnosis of gonorrhoea[14,85,101,115] (TABLE 3). POCTs could provide a definitive, rapid diagnosis to guide specific treatment in situations where this is not currently possible, such as in settings in which only syndromic management is available, in cases where patients may not return for treatment and for screening asymptomatic patients[116–118]. Ideally, POCTs should meet the 'ASSURED' criteria, that is, be affordable, sensitive, specific, user-friendly, robust and rapid, and equipment free (or requiring minimal equipment powered by solar or battery sources)[117,119,120]. However, all diagnostic tests that provide rapid test results and correct treatment during a single clinical visit could be defined as POCTs[117,121,122]. The Gram stain is an oft-used POCT; its benefits and limitations have been described above[122,123]. Other POCTs developed for *N. gonorrhoeae* include lateral flow immunochromatographic and optical immunoassay tests based on antigen detection, as well as a near-POCT NAAT — the Xpert CT/NG assay[101,120,122,123]. Recent reviews of the performance of several POCTs have shown that immunochromatographic-based and optical immunoassay-based POCTs had highly suboptimal sensitivities, some as low as 12.5%, and specificities ranging from 89% to >97%[120,123] and, therefore, are not recommended. However, mathematical modelling has shown that the sensitivity required for POCTs to be effective may be lower in settings where

Table 3 | **POCTs, near-POCTs and antimicrobial resistance tests available and in the pipeline**

Platform/test	GeneXpert Xpert CT/NG[a]	Binx io CT/NG	ID NOW CT/NG[b]	Truenat CT/NG	ResistancePlus GC[c]
Manufacturer	Cepheid	Atlas Genetics	Abbott	Molbio	SpeeDx
Instrument; health-care setting	Table-top, not portable (used in mobile clinics); level 2	Table-top, portable; level 1	Table-top, portable; level 1	Table-top, portable; level 1–2	Table-top PCR machines, not portable; level 2
Amplification technology	Real-time PCR	NAAT, immunoassay and small molecule chemistry	Isothermal PCR	Real-time PCR	Real-time PCR
Specimen	Female and male urine; endocervical swab; and patient-collected vaginal swab	Self-collected and clinician-collected vaginal swabs from symptomatic and asymptomatic females; and urine from males	TBD	Endocervical and vaginal swabs; male urethral swab; and male and female urine	Male and female urine; rectal, cervical, vaginal, urethral, pharyngeal, and ocular swabs; and ocular extracts
Procedure	~4 steps, sample preparation automated	~4 steps, sample preparation automated	~6 steps, raw sample added to device	Multiple pipetting steps	~4 steps
Time to result	~90 min	30 min	15 min	~60 min	50 min
Reagent stability	3 years	Cartridges with reagents stable at 2–25°C	>12 months	2 years at temperatures 2–30°C	18–24 months
Energy requirements	Mains power required; solar power possible, can be powered by 12V DC or 120V AC	Mains power required	AC mains and DC from external AC/DC supplied plug pack	Rechargeable lithium ion battery	Mains power required
Training	<0.5 days	<1 h	<0.5 days	<0.5 days	<0.5 days
Connectivity	Yes, computer required, remote calibration	Yes, via middleware	Yes, USB and ethernet outlets	Yes, wireless connectivity: Wi-Fi, bluetooth, SMS	Yes, computer required
Regulatory compliance	FDA, CE-IVD	CE-IVD, FDA approval pending	NA	CE-IVD approval pending	CE-IVD, FDA approval pending

This table is not an exhaustive list of all point-of-care tests (POCTs) in the pipeline; the tests listed were selected owing to more information being available[101,170]. CE-IVD, European Conformity In Vitro Diagnostic; NA, not available; Level 1, primary health-care centre; Level 2, district hospital; NAAT, nucleic acid amplification test; TBD, to be determined. [a]Near-POCT. [b]Previously named Alere i CT/NG. [c]First licensed molecular test detecting both *Neisseria gonorrhoeae* and its ciprofloxacin susceptibility status[101,170].

there is a high risk for transmission because treatment is delayed pending testing results or patients do not return for treatment[124]. The Xpert CT/NG assay has been successfully implemented as a near-POCT in areas such as Papua New Guinea, South Africa and remote regions of Australia[6,101,115,125,126]. However, this test is expensive, needs substantial electricity, and results take ~90 min.

Screening and prevention

Screening general populations for gonococcal infections is not indicated. However, screening or opportunistic testing can be considered for individuals at higher risk of gonococcal infection. These populations include the sexually active youth, sexual contacts of individuals having a suspected gonococcal infection, MSM, individuals with new or multiple sexual partners, individuals with HIV infection or a history of STIs, sex workers and their sexual partners, and women (≤35 years of age) and men (≤30 years of age) at initial admission to a correctional facility[6,13,83,127,128]. The US Centers for Disease Control and Prevention guidelines recommend annual screening for gonorrhoea of all sexually active females <25 years of age and older women at increased risk of infection, and screening should also be offered to young MSM[127,128]. More recently, in the USA, owing to observed high rates of incident infections, screening for gonorrhoea and other bacterial STIs (*C. trachomatis* infections and syphilis) has been recommended at 3–6-month intervals for individuals receiving HIV PrEP[129]. In other high-income settings, there are no screening recommendations for the general population owing to the low cost-effectiveness and low population prevalence of gonorrhoea, which results in low positive predictive values of the testing and increased probability of false positive results, which could cause considerable harm for patients and their partners. No aetiologically based screening is performed in any low-income settings.

Main prevention efforts include education regarding symptomatic and asymptomatic gonorrhoea and other STIs; promotion of safe sexual behaviours (for example, increased condom use through condom-promotion education and campaigns); behaviour change communication programmes (for example, promoting fewer unknown, casual and unprotected sexual contacts and early health-seeking behaviour); improved sexual partner notification and treatment; and expansion of targeted interventions, including screening in some settings for vulnerable populations (sex workers, MSM, adolescents and patients with STIs and their sexual partners)[130].

Vaccines. Given the threat of untreatable gonorrhoea due to the spread of AMR and the high burden of gonorrhoea worldwide, the need for a gonococcal vaccine has become increasingly urgent[131–133]. Prior to the 1990s,

four vaccine candidates progressed to clinical trials: a whole cell vaccine, a partially autolysed vaccine, a pilus-based vaccine and a PorB-based vaccine[133–135]; none provided much protection from infection. Gonococcal vaccine development is complicated by the biology of the gonococcus. Limitations include the scarce adaptive immune responses to gonococcal infections, lack of known correlates of protection, antigenic variability of the potential vaccine candidate antigens, production of blocking antibodies (which upon binding their target prevent the binding of other antibodies — for example, bactericidal antibodies — to the same target or other targets in close proximity) to conserved antigens, and lack of robust, small laboratory animals for testing vaccines[132,134].

However, recently, it has been noted in several countries that there was a decline in the number of gonorrhoea cases following the use of meningococcal group B OMV vaccines against *N. meningitidis*[136]. One of these vaccines, with the trade name MeNZB, was associated with reduced rates of gonorrhoea diagnosis and of hospitalization from gonorrhoea[136], and it seems to provide proof-of-principle to inform the development of gonococcal vaccines[137,138]. Research to elucidate the specific or nonspecific antigens and mechanisms involved in the MeNZB-mediated protection against gonorrhoea is crucial. MeNZB is no longer available; however, the licensed, four-component meningococcal group B vaccine 4CMenB (trade name BEXSERO; GlaxoSmithKline) includes the same OMV as MeNZB and three recombinant meningococcal antigens (Neisserial heparin-binding antigen, factor H-binding protein and Neisseria adhesin A), which are also relatively conserved compared with their gonococcal homologues[139]. Accordingly, high coverage of the 4CMenB in the population may also decrease gonorrhoea prevalence. Recently, research has exploited OMVs from *N. meningitidis* expressing factor H-binding protein and found that serum bactericidal antibodies against the gonococcus were produced in mice, although sera from humans immunized with 4CMenB were not bactericidal for *N. gonorrhoeae*[140]. These findings, together with the immunobiology research (including on *N. gonorrhoeae* immune suppressive responses and how they can be overcome), antigen discovery and animal modelling, are promising for vaccine development.

Management

Management principles

Gonorrhoea is a community-based infection and often there is limited follow-up after treatment. Prompt and effective treatment reduces complications and eliminates transmission of the infection[128]. Since there are no vaccines, and host immunity cannot prevent reinfection, eradication of infections is solely reliant upon case finding and ideally microbiological diagnosis coupled with effective antimicrobial treatment[128]. Of note, because gonorrhoea also amplifies the risk for acquisition and transmission of HIV, gonorrhoea control also contributes to global efforts to reduce HIV infections. The goal of gonorrhoea management is to quickly and accurately identify infected individuals, enabling provision of timely treatment to prevent complications and transmission of infection to sexual partners and, for pregnant women, to children at the time of birth. Factors influencing management include considerations of the clinical manifestations, the disproportionate morbidity for women (PID, infertility, ectopic pregnancy and chronic pelvic pain), and stigma associated with STIs. As the infection is most common in resource-limited settings (even in high-income nations gonorrhoea is most common among marginalized populations who may have limited resources and/or limited access to health care), costs of both diagnosis and treatment may also influence the translation of management principles into practice.

Because gonorrhoea transmission most often is a consequence of sex with a person who is unaware of their infection, notification, testing and treatment of recent sexual partners is a crucial part of gonorrhoea management within communities[82,141]. Notification and referral of exposed sexual partners of individuals with STIs (by health-care providers, public health specialists or the partner themself) has been recommended since at least the 1940s[142]. However, programmes promoting notification of sexual partners have often proved resource intensive and failed to successfully lead to treatment of many sexual partners, probably in part owing to stigma and embarrassment regarding having an STI. Thus, 'expedited partner therapy' or 'partner-delivered therapy' (that is, the partner(s) of a patient with gonorrhoea receives oral, single dose antimicrobials delivered by the patient, without have being examined or tested) for gonococcal and chlamydial infections has been increasingly practiced in the USA with good results[143]. Currently, cefixime plus azithromycin is used for expedited partner therapy for heterosexual men and women[128]. However, this approach has raised concerns about the lack of clinical examination, lack of testing for additional STIs, lack of opportunities to trace 'downstream' sex partners, possible antimicrobial allergy or adverse events experienced by the partner(s) and AMR emergence.

Antimicrobial therapy

Syndromic management of urethral discharge in men can be relatively effective for gonorrhoea[116]. However, appropriate, local and aetiologically based studies to regularly refine the syndromic management algorithm(s) are imperative, and nevertheless some infections (for example, *C. trachomatis* and *Mycoplasma genitalium* infections) cannot be distinguished from gonorrhoea, resulting in overtreatment. Syndromic management of vaginal discharge both fails to detect and treat the substantial proportion of asymptomatic infections in women (who might continue to transmit the infection) and leads to vast overtreatment of symptomatic women who do not have gonorrhoea but who do have *C. trachomatis*, *M. genitalium* or *Trichomonas vaginalis* infection or bacterial vaginosis[109,116].

Single-dose, directly observed systemic therapy (as topical therapy has not proved effective) that is provided in the care setting is preferred to ensure medications are delivered. Dual antimicrobial therapy (mainly parenteral ceftriaxone plus oral azithromycin) is currently recommended for empirical first-line therapy by the WHO

global guidelines[109] and in most high-income countries, including European countries[82], the USA[128], Canada[144] and Australia[145]; however, in some countries (for example, Japan[146] and, since 2019, the UK[114]) ceftriaxone high-dose (1 g) monotherapy is recommended[147–149]. In some international and national guidelines, cefixime plus azithromycin is recommended as an alternative regimen, but only if ceftriaxone is not available or the injection is refused[82,128]. There is an ongoing debate among experts as to whether single or dual antimicrobial therapy should be the recommended therapy for uncomplicated gonorrhoea. The rationale for introducing dual therapy was to address the problem of *C. trachomatis* co-infection, which occurs in 10–40% of individuals with urogenital gonorrhoea[150], as well as a hypothetical benefit of reducing the emergence and/or spread of AMR (particularly resistance to ceftriaxone) in *N. gonorrhoeae*. When possible, well tolerated oral therapy is preferred by both patients and clinicians[151]. Finally, individuals with gonorrhoea are often co-infected with other pathogens, including *C. trachomatis*, *T. vaginalis*, *Treponema pallidum* and/or *M. genitalium* and, therefore, require treatment either with agents that are also effective against these pathogens or with co-therapy.

The continuing development of AMR by the gonococcus, coupled with a diminished pipeline for the development of new antimicrobials have narrowed available therapies for gonorrhoea to a single agent that is sufficiently effective for first-line monotherapy (that is, parenteral ceftriaxone[16,152]), which is frequently given together with azithromycin. If ceftriaxone is unavailable, the patient has β-lactam antimicrobial allergy or the patient is infected with a ceftriaxone-resistant gonococcal strain, therapy is challenging and highly variable, often requiring ciprofloxacin monotherapy (if the gonococcal strain causing the infection has been proven susceptible by phenotypic or genetic resistance testing[82,114]), high-dose (2 g) azithromycin monotherapy, spectinomycin (together with high-dose azithromycin, particularly if pharyngeal gonorrhoea has not been excluded) or gentamicin (together with high-dose azithromycin, particularly if pharyngeal gonorrhoea has not been excluded)[82,128]. However, each of these alternate therapies has limitations related to gonococcal resistance, antimicrobial availability and/or patient tolerance. Progressive decreases in susceptibility of *N. gonorrhoeae* to ceftriaxone, as well as to other antimicrobials, create a pressing need for continued monitoring of gonococcal AMR through surveillance networks such as the WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO GASP)[15,153], the European GASP (Euro-GASP)[154–156] and the US Centers for Disease Control and Prevention Gonococcal Isolate Surveillance Project (GISP)[157,158]; Euro-GASP and GISP additionally collect clinical and epidemiological data on the corresponding patients.

Practical applications

Gonorrhoea remains a global public health threat. The biological characteristics of *N. gonorrhoeae* and its proven propensity to develop AMR, the varied clinical manifestations of the infection that may not be obvious or pathogen-specific (particularly for women and extragenital infections), and the limited resources that are dedicated to gonorrhoea control all contribute to the limited success of present gonorrhoea control efforts. Therapy may be hindered by the lack of recommended, high-quality antimicrobials. Current main reliance on only one consistently effective antimicrobial (injectable ceftriaxone) may make effective treatment difficult. Perceptions by patients that they may be resistant or allergic to β-lactam antimicrobials, including ceftriaxone, the logistical constraints of parenteral therapy and fear/avoidance of injections may result in the use of less-effective oral therapy. Therapy is also limited in some regions by suboptimal or complete absence of surveillance of infection and particularly AMR, leading to treatment with antimicrobials that are ineffective. Although improved surveillance has increased appreciation of the threat of AMR, this surveillance is not fully representative, being insufficient or even lacking in areas where the infection is most common[15,153,159].

On the policy level, limited health-care resources directed towards this public health problem (in low-income and middle-income nations and even in high-income nations) have created a tension between diagnostic test cost and ensuring a ready supply of medications for gonorrhoea control. The cost of paying for diagnostic testing may erode the funds available for therapy, thereby forcing public health officials to prioritize screening initiatives. In recent years, clinical microscopy (Gram stain) as a low-cost POCT has become less available, owing to the lack of availability of microscopes and adequate technical training in the methodology.

All these challenges are sometimes amplified by social factors. Stigma is a pervasive and powerful force that affects the prioritization of gonorrhoea as a public health problem and influences the behaviour of individuals with, or at risk for, gonorrhoea with regard to health care-seeking behaviour and partner notification. Stigma also affects health-care provider attitudes and practices, including evaluation of STI risk and appropriate screening[159].

At the individual level, few individuals wish to identify themselves as being at risk for STIs, potentially inhibiting discussion of STI risk with their health-care provider, prevention measures and seeking evaluation for genitourinary symptoms and signs. Limited access to health care may also prevent or delay recommended STI screening or evaluation of symptoms when present. Finally, individuals diagnosed with gonorrhoea or other STIs may fail to notify their sex partners of their risk of infection, thereby increasing the probability of complications or continuing transmission.

Clinicians too are sometimes hindered by perceived social factors in evaluating and managing individuals with or at risk for STIs. Busy clinicians may assume that their patients are not at risk or hesitate to take sexual histories without a cue to action from their patients, such as a history of possible exposure or genitourinary symptoms or signs, worrying that to ask such questions might be offensive to patients, when data in fact indicate that, if properly presented, this is not the case[159]. Clinician reticence, along with individual embarrassment and/or shame may also hinder partner notification.

Thus, although the principles of gonorrhoea management are well known, there are numerous areas within the current management strategies that need to be improved.

Quality of life

As gonorrhoea is an STI, its diagnosis is often associated with perceptions of social stigma, shame and denial, and can lead to intense embarrassment and fear of retaliation, domestic violence or loss of relationships, including marriages[160]. In the 1960s, the sociologist Erving Goffman described stigma as "undesired differentness" and "discrediting"[161] — a finding reinforced by research findings in the 1990s showing that STI-related stigma resulted in lower testing rates for gonorrhoea[162]. More recent studies have shown that stigma in different populations contributes to a reduction in seeking testing for STIs, reluctance to notify sexual partners and lower levels of treatment compliance[163,164]. For example, in Bhutan, perceived stigma was identified as a key reason for high levels (>50%) of loss to follow-up among patients diagnosed with gonorrhoea[165]. Research found that common coping strategies among people with gonorrhoea in an urban American setting included denial and disengagement — although these behaviours did not greatly affect rates of partner notification[166]. These findings, specific to gonorrhoea, are illustrative of more general findings that stigma influences STI care-seeking. Research noted a reluctance to seek STI testing in young women from socioeconomically marginalized neighbourhoods in Canada, owing to "stigma and the fear of being ostracized"[167] and studies found that, among African–American men, increasing STI-related stigma was "significantly associated with…decreased odds of having been tested, [and]…decreased willingness to notify nonmain partners"[168]; these factors may contribute to the observed disparities in the distribution of STIs across the intersectional inequalities of ethnicity and gender[169]. In Tigray, Ethiopia, rates of loss to follow-up were lower among patients with low levels of STI-related stigma than in study participants reporting high levels of stigma[164].

At the policy level, stigma around gonorrhoea probably contributes to the widespread lack of attention and resource allocation within public health global and national programmes. A recent review of the challenges and opportunities for STI control argued that stigma associated with gonorrhoea and other STIs arises, in part, from 'condemnatory moral attitudes' around the behaviours leading to risk of infection — in particular same-sex relationships and transactional sex[170]. Earlier research investigating gonorrhoea control in the USA in the 1970s and 1980s similarly argued that "society's propensity to view gonorrhoea as a disease of 'immoral' people" directly contributed to the lack of resources and attention paid to the infection[171]. Qualitative research on the lack of political prioritization afforded to STI control in China confirmed that STIs received a lower place on the health agenda than HIV infection, as decision makers associated them with 'immorality' and patients were considered 'condemnable'[172].

Arguably, the high levels of stigma and accompanying negative framing of gonorrhoea and other STIs exert the most substantial effect on quality of life measures associated with gonorrhoea. Perceptions of embarrassment and humiliation that a diagnosis may bring — both for the affected individuals and their sexual partners — combined with under-resourced public health control programmes, contribute to undiagnosed or poorly treated infections, thereby increasing risks of onward transmission and individual clinical complications and longer-term sequelae caused by this otherwise treatable infection.

Paradoxically, the rise of AMR in *N. gonorrhoeae* may, potentially, force policy-level decision makers to act to devote more attention to the prevention and control of gonorrhoea. However, it should be emphasised that interventions to tackle gonococcal AMR are only likely to succeed if they address not only questions of appropriate antimicrobial use/misuse, but also aim to decrease the global burden of gonorrhoea, which also requires reducing the perception of associated shame and stigma. Effective interventions to decrease stigma and increase patient quality of life should be directed not only at individual and community levels, but also at the political level, to identify and address the social conditions giving rise to stigma and promote institutional fairness[173].

Outlook

It is imperative to address many global issues for the successful management and control of gonorrhoea. These key priorities and research efforts span all fields, from epidemiology of the pathogen and the disease to the quality of life of patients (BOX 2). Of note, reducing the perception of shame, humiliation and stigma that is associated with a diagnosis of gonorrhoea and with certain sexual orientations (for example, MSM) in many settings is crucial to obtain more accurate incidence and prevalence data and to decrease the global burden of gonorrhoea, which would also substantially reduce gonococcal AMR. Effective interventions to decrease STI-associated stigma should be implemented at individual and community levels, and at the social and political levels where social conditions giving rise to stigma should be identified and tackled[173]. Gonorrhoea and other STIs need to be considered and managed by individuals, the health system, the general community and at the political level in all countries in recognition of the right to health services free of discrimination and without stigma.

Epidemiology

The incidence of gonorrhoea is increasing, especially in high-income settings globally. However, global population-based incidence and prevalence data are extremely scarce from most settings and, even in high-income settings where surveillance is conducted in a more systematic and regular manner, the surveillance data should be interpreted with caution as the surveillance systems, diagnostic testing, methodologies and quality assurance are not standardized across countries and remain weak in several settings[33,36]. Additionally, the current prevalence of serious complications and sequelae due to gonorrhoea is mainly unknown and estimates are mostly based on historical data. WGS will revolutionize

our understanding of the molecular epidemiology (that is, the geographical and temporal spread) of *N. gonorrhoeae* strains. WGS is substantially more accurate than previously used molecular epidemiological typing methods and can adequately describe the emergence, transmission and evolution of AMR gonococcal strains both geographically and temporally, as well as predict AMR with adequate accuracy[45,156,174–184]. However, it is important to strongly emphasize that the full benefits of using WGS for both molecular and infection epidemiology can only be achieved if the WGS data are linked to phenotypical data for the gonococcal isolates and the clinical and epidemiological data for the corresponding patients with gonorrhoea. Notably, WGS of gonococcal isolates with joint analysis of clinical and epidemiological data has also already been introduced and provided increased understanding of, for example, the distribution of AMR and susceptible gonococcal strains in different populations nationally and regionally in the international Euro-GASP (which currently includes 27 European countries)[156].

Box 2 | **Key priorities in gonorrhoea research and control**

- Decreasing the perception of stigma, humiliation and shame associated with gonorrhoea and other sexually transmitted infections (STIs), and ensuring that services and interventions are delivered free of discrimination, leaving no populations behind

Epidemiology

- Increasing knowledge of the incidence and prevalence of the infection and its complications and sequelae in the general population and subpopulations
- Expanding global antimicrobial resistance (AMR) surveillance (phenotypic and genetic AMR testing), including surveillance of treatment failures and antimicrobial use/misuse, in combination with whole-genome sequencing and clinical and epidemiological data from patients

Mechanisms/pathophysiology

- Improving knowledge of the natural course and pathogenesis, including genomic, physiological, pathogenic and virulence mechanisms of *Neisseria gonorrhoeae* in different anatomical sites and understanding the emergence, evolution, spread and biological costs or benefits (fitness) of AMR
- Understanding of pharmacokinetics and pharmacodynamics of current and future therapeutic antimicrobials in urogenital and particularly extragenital sites, to inform treatment guidelines

Diagnosis, screening and prevention

- Increasing diagnostic testing (also to detect asymptomatic gonorrhoea), increasing use of validated and quality-assured nucleic acid amplification tests and developing rapid, appropriate and affordable point-of-care tests, which should also enable simultaneous prediction of AMR or susceptibility status
- Strengthening prevention (for example, increasing the use of condoms and of out-of-box approaches, such as the use of antiseptic mouthwash to prevent acquisition and transmission of pharyngeal gonorrhoea[215])
- Improving the understanding of the effects of pre-exposure prophylaxis on the prevalence of gonorrhoea and other STIs in different populations, the risk factors involved, and the ideal counselling, monitoring and screening intervals for individuals taking pre-exposure prophylaxis
- Developing gonococcal vaccine(s), for which substantial progress has been made in recent years[131–134,136–138,189,191,216]

Management

- Promoting early diagnosis and treatment of patients and their partners, following evidence-based international and national guidelines
- Promoting responsible antimicrobial use and stewardship (both STI-related and on a population level), as excessive antimicrobial use can decrease the susceptibility of *N. gonorrhoeae* to therapeutic drugs, both directly (through selection of AMR in *N. gonorrhoeae*) and indirectly (through selection of AMR determinants in, for example, commensal *Neisseria* spp. that are subsequently shared through horizontal genetic transfer with *N. gonorrhoeae*[217])
- Developing novel therapeutic antimicrobials and strategies to preserve the efficacy of current and future antimicrobials

Mechanisms

Our understanding of the pathophysiology of gonorrhoea is still limited in many areas, especially the natural course of the infection (including duration and spontaneous resolution), the dynamics of pathogenesis and infection (such as transmission, average time to detection and treatment in different populations, effects of treatment (or co-treatment for other concomitant STIs) on innate and adaptive immunity, host damage and possible host protection) and immune responses and their suppression in urogenital and particularly extragenital sites, such as the pharynx. Improving the knowledge in these areas would enable us to more effectively use mathematical modelling in the gonorrhoea and gonococcal AMR field, taking into account microbiological, genomic, evolutionary, clinical, immunological and epidemiological data[185], as well as in vaccine development.

After the introduction of any new therapeutic antimicrobial for gonorrhoea, *N. gonorrhoeae* has rapidly acquired or developed decreased susceptibility or resistance to it (FIG. 1) via several AMR mechanisms: enzymatic destruction or modification of the antimicrobial, modification or protection of antimicrobial targets to avoid binding, increased export of the antimicrobial (for example, through the MtrC–MtrD–MtrE efflux pump) and decreased uptake of the antimicrobial (for instance, through the porin PorB)[16]. Some AMR determinants, particularly target alterations, directly cause AMR, whereas others cannot result in AMR on their own and require the presence of additional AMR determinants. The accumulation of many AMR determinants does not seem to substantially reduce the biological fitness of *N. gonorrhoeae*[16–21], and some AMR determinants seem to even enhance the fitness of specific gonococcal strains[19–21]. Nevertheless, we need to substantially improve our understanding and definition of fitness as well as of compensatory mutations that could restore possible fitness cost in *N. gonorrhoeae*. We need detailed knowledge regarding how gonococcal AMR determinants affect the fitness of gonococcal strains, how fitness affects the emergence and spread of AMR strains and how these strains become established in the circulating gonococcal populations. Thus, we need to investigate how the fitness of AMR strains may affect the competition with wild-type antimicrobial susceptible strains (which is mainly the current fitness definition in microbiological research) and its effects on several other factors, such as transmissibility, duration of infection in different anatomical sites and proportion of symptomatic and asymptomatic infections and severe complications and sequelae in heterogeneous populations with different sexual behaviours. Further research is also needed to identify and characterize in detail known or novel AMR determinants in clinical gonococcal isolates

(including their induction and selection, evolution, effect on AMR and biological fitness) and to develop and evaluate genetic AMR prediction tests that can supplement the culture-based AMR surveillance.

Diagnosis, screening and prevention

In many settings, mostly in less-resourced areas (in which frequently the prevalence of gonorrhoea is the highest), the diagnosis, testing, case reporting and prevention of gonorrhoea remain suboptimal. Thus, it is important to widely implement the use of cost-effective, appropriate and quality-assured NAATs. If required, these NAATs can be performed in centralized reference laboratories for cost-effectiveness and to maintain a high level of quality assurance. In addition, rapid, appropriate POCTs for the diagnosis of gonorrhoea and other STIs are urgently needed. Gonococcal POCTs should ideally simultaneously predict AMR to inform treatment. For some antimicrobials, such as ciprofloxacin, mathematical modelling has indicated that POCTs with high sensitivity to detect AMR can be more effective than NAATs and even culture to preserve the effectiveness of the antimicrobial. By contrast, POCTs detecting *N. gonorrhoeae* without reliable AMR detection may accelerate the spread of AMR gonococcal strains[186]. Several rapid, sensitive and specific NAAT-based POCTs for gonorrhoea are in the pipeline and will be available in the coming few years[101,122,170,187] (TABLE 3). Accordingly, it will soon be essential to prepare health-care systems for use of these POCTs by including them in STI training modules, management guidelines, diagnostic algorithms and regulatory frameworks. Limitations to the adoption of POCTs are considerable and include time for results; cost of the instrument; lack of required infrastructure, quality assurance and reporting criteria; supply chain issues that may discourage use; lack of clear recommendations on the inclusion of POCTs in diagnostic algorithms and regulatory frameworks, lack of training opportunities and education of health-care workers about the utility and advantages of POCTs; and worries by laboratory-based personnel that out-of-laboratory testing may infringe on job security[118].

In an era of high prevalence of AMR in *N. gonorrhoeae* coupled with the widespread use of diagnostic gonococcal NAATs internationally, it is essential to retain and strengthen the ability to perform gonococcal culture, which is the only method that enables complete AMR testing, because surveillance of gonococcal AMR (preferably minimum inhibitory concentration (MIC)-based) and ideally also of cases of treatment failure is imperative. In settings where NAATs solely are used for the diagnosis of gonorrhoea, participation in organized and quality-assured national, regional and/or international GASPs is crucial.

WGS and other new technologies such as transcriptomics and proteomics are also informing the development of *N. gonorrhoeae* diagnostics and vaccines[156,174–183,188–191]. For developing gonococcal vaccines, a number of promising protein antigens have been described and characterized, including proteins involved in colonization (for example, PilC, PilQ, PorB, Opa and OmpA), evasion of innate defences (for example, MtrE, SliC, Ng-ACP, MsrAB, Lst and PorB) and nutrient acquisition (for example, TbpA, TbpB, LbpA and LbpB); structural proteins (for example, BamA, BamE, NGO2054 and NGO2111); other proteins such as AniA (implicated in nitrate reduction) and MetQ (methionine transporter that promotes survival in macrophages); the 2C7 epitope (peptide mimetic of LOS epitope); and OMVs[131,132,134]. Many of the promising new vaccine targets for *N. gonorrhoeae* have been identified through proteomic approaches and transcriptome analysis of genes expressed during gonococcal infections[188–190,192]. Furthermore, to overcome the restrictions of the current model of female mice treated with 17β-oestradiol, new animal models for *N. gonorrhoeae* infection are being developed, such as transgenic mice that mimic human infections and express human cell adhesion molecules or iron-binding molecules[193,194], and a transgenic mice model expressing human complement factor H is available for the closely related *N. meningitidis*[195].

Management

Currently available genetic assays have shortcomings (such as cross-reactions with nongonococcal *Neisseria* species in clinical, particularly pharyngeal, specimens, and suboptimal sensitivity and/or specificity) that limit their prediction of resistance or susceptibility to currently recommended therapeutic antimicrobials (except for ciprofloxacin, for which the sensitivity and specificity of NAATs are generally >95%); additionally, newly emerging AMR determinants are not detected[196–198]. However, future improved rapid POCTs that detect both *N. gonorrhoeae* and its resistance or susceptibility to several antimicrobials will guide individualized therapy at the first health-care visit and restrict the use of last-line antimicrobials[196–199]. Such POCTs will improve the management and control of both gonorrhoea and *N. gonorrhoeae* AMR. WGS can also be used for prediction of AMR and MICs of antimicrobials with reasonably high accuracy[156,182–184]. Rapid, real-time sequencing with the hand-held MinION sequencer was shown to generate fairly accurate genome sequences and be able to predict resistance to ciprofloxacin and azithromycin and decreased susceptibility or resistance to cefixime in *N. gonorrhoeae*[183]. The rapid development of WGS technologies with decreasing complexity and cost and faster turnaround times may make these technologies suitable for *N. gonorrhoeae* detection and prediction of resistance or susceptibility to therapeutic antimicrobials at the diagnostic setting, including at point-of-care.

The global issue of AMR in *N. gonorrhoeae* will probably continue to escalate, and we cannot rely on the last-line ceftriaxone (plus azithromycin) indefinitely. Consequently, new antimicrobials, with novel mechanisms of action, for monotherapy and/or inclusion in dual therapies for urogenital and extragenital gonorrhoea are crucially needed. Some recently developed new antimicrobials, namely, the spiropyrimidinetrione zoliflodacin[200–204] and triazaacenaphthylene gepotidacin[205–207], will both soon be in phase III randomized clinical controlled trials for uncomplicated gonorrhoea. Additional promising novel antimicrobials in earlier development that deserve further attention for the

treatment of gonorrhoea (and possibly additional STIs) are, for example, lefamulin[208,209] and SMT-571 (REF.[210]). However, until novel antimicrobials are available, it is imperative to increase our knowledge regarding ideal treatment, including dosing regimens, of gonorrhoea and other STIs, such as *C. trachomatis* and *M. genitalium* infections, with the available antimicrobials ceftriaxone, azithromycin and doxycycline. Clearly, a more holistic view on the treatment of bacterial STIs and understanding the effect of any new bacterial STI treatment on other STI pathogens and the bystander microbiota is essential. Current knowledge regarding the pharmacokinetics and pharmacodynamics of the available antimicrobials in the treatment of gonorrhoea and other STIs at urogenital and particularly extragenital sites is highly limited[211] and requires substantially increased attention to inform ideal dosing regimens, and multiple dose regimens for gonorrhoea might be required.

Published online: 21 November 2019

1. Edwards, J. L., Shao, J. Q., Ault, K. A. & Apicella, M. A. *Neisseria gonorrhoeae* elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells. *Infect. Immun.* **68**, 5354–5363 (2000).
2. Evans, B. A. Ultrastructural study of cervical gonorrhea. *J. Infect. Dis.* **136**, 248–255 (1977).
3. Barlow, D. & Phillips, I. Gonorrhoea in women. Diagnostic, clinical, and laboratory aspects. *Lancet* **1**, 761–764 (1978).
4. Schmale, J. D., Martin, J. E. Jr & Domescik, G. Observations on the culture diagnosis of gonorrhea in women. *JAMA* **210**, 312–314 (1969).
5. Quillin, S. J. & Seifert, H. S. *Neisseria gonorrhoeae* host adaptation and pathogenesis. *Nat. Rev. Microbiol.* **16**, 226–240 (2018).
This review discusses sex-related symptomatic gonorrhoea and provides a detailed overview of the bacterial factors, on molecular levels, that are important for the different stages of pathogenesis, including transmission, colonization and immune evasion.
6. Elias, J. F. & Vogel, U. in *Manual of Clinical Microbiology* 12th edn Vol. 1(eds Carroll, C. C. et al.) 640–655 (American Society for Microbiology, 2019).
7. Adeolu, M. & Gupta, R. S. Phylogenomics and molecular signatures for the order Neisseriales: proposal for division of the order Neisseriales into the emended family Neisseriaceae and Chromobacteriaceae fam. nov. *Antonie van Leeuwenhoek* **104**, 1–24 (2013).
8. Tønjum, T. & van Putten, J. in *Infectious Diseases* 4th edn (eds Cohen, J., Powderly, W. G. & Steven M. Opal) 1553-1564 (Elsevier, 2016).
9. Liu, G., Tang, C. M. & Exley, R. M. Non-pathogenic Neisseria: members of an abundant, multi-habitat, diverse genus. *Microbiology* **161**, 1297–1312 (2015).
10. Johnson, A. P. The pathogenic potential of commensal species of Neisseria. *J. Clin. Pathol.* **36**, 213–223 (1983).
11. Seifert, H. S. Location, location, location — commensalism, damage and evolution of the pathogenic Neisseria. *J. Mol. Biol* **431**, 3010–3014 (2019).
12. Hook, E. W. 3rd & Handsfield, H. H. in *Sexually Transmitted Diseases* (eds Holmes, K. K. et al.) 4th edn, 627–645 (McGraw-Hill Education, 2008).
This comprehensive chapter describes different clinical manifestations of gonorrhoea.
13. Public Health Agency of Canada. *Canadian Guidelines on Sexually Transmitted Infections — Management and treatment of specific infections — Gonococcal Infections* (Government of Canada, Ottawa, 2013) (modified Sept 2017).
14. World Health Organization. *Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae* (World Health Organization, 2012).
15. Wi, T. et al. Antimicrobial resistance in *Neisseria gonorrhoeae*: global surveillance and a call for international collaborative action. *PLoS Med.* **14**, e1002344 (2017).
16. Unemo, M. & Shafer, W. M. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. *Clin. Microbiol. Rev.* **27**, 587–613 (2014).
This review provides an extensive overview regarding gonorrhoea treatment regimens and emerging antimicrobial resistance, including genetic and phenotypic AMR determinants.
17. Wadsworth, C. B., Arnold, B. J., Sater, M. R. A. & Grad, Y. H. Azithromycin resistance through interspecific acquisition of an epistasis-dependent efflux pump component and transcriptional regulator in *Neisseria gonorrhoeae*. *mBio* **9**, e01419–18 (2018).
18. Rouquette-Loughlin, C. E. et al. Mechanistic basis for decreased antimicrobial susceptibility in a clinical isolate of *Neisseria gonorrhoeae* possessing a mosaic-like mtr efflux pump locus. *mBio* **9**, e02281–18 (2018).
19. Kunz, A. N. et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. *J. Infect. Dis.* **205**, 1821–1829 (2012).
20. Warner, D. M., Folster, J. P., Shafer, W. M. & Jerse, A. E. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of *Neisseria gonorrhoeae*. *J. Infect. Dis.* **196**, 1804–1812 (2007).
21. Warner, D. M., Shafer, W. M. & Jerse, A. E. Clinically relevant mutations that cause derepression of the *Neisseria gonorrhoeae* MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. *Mol. Microbiol.* **70**, 462–478 (2008).
22. Rowley, J. et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. *Bull. World Health Organ.* **97**, 548–562P (2019).
23. Adler, M., Foster, S., Richens, J. & Slavin, H. *Sexual Health and Care. Sexually Transmitted Infections, Guidelines for Prevention and Treatment*. Health and Population Division Occasional Paper 136 (Overseas Development Administration, London, 1996).
24. Aral, S. O. *et al*. in *Sexually Transmitted Diseases*, 4th edn (eds Holmes, K. K. et al.) 54–92 (McGraw-Hill, 2008).
25. Dallabetta, G. A., Laga, M. & Lamptey, P. R. *Control of Sexually Transmitted Diseases: A Handbook for the Design and Management of Programs* (AIDSCAP/Family Health International, 1996).
26. Aral, S. O., Fenton, K. A. & Holmes, K. K. Sexually transmitted diseases in the USA: temporal trends. *Sex. Transm. Infect.* **83**, 257–266 (2007).
27. Fenton, K. A. & Lowndes, C. M. Recent trends in the epidemiology of sexually transmitted infections in the European union. *Sex. Transm. Infect.* **80**, 255–263 (2004).
28. Mohammed, H. et al. 100 years of STIs in the UK: a review of national surveillance data. *Sex. Transm. Infect.* **94**, 553–558 (2018).
29. Centers for Disease Control and Prevention. Tracking the hidden epidemics, trends in STDs in the United States 2000. *CDC* www.cdc.gov/std/trends2000/trends2000.pdf (2000).
30. Centers for Disease Control and Prevention. STDs in men who have sex with men. *CDC* https://www.cdc.gov/std/stats17/msm.htm. (2017).
31. Centers for Disease Control and Prevention. New CDC analysis shows steep and sustained increases in STDs in recent years. *CDC* https://www.cdc.gov/media/releases/2018/p0828-increases-in-stds.html (2018).
32. Centers for Disease Control and Prevention. Gonorrhea. *CDC* https://www.cdc.gov/std/stats17/gonorrhea.htm (2017).
33. European Centre for Disease Prevention and Control Surveillance Atlas of Infectious Diseases. Surveillance atlas of infectious diseases. *ECDC* https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases (2017).
34. Public Health England. Health Protection Report volume 12 issue 20: news (8 June). *PHE* https://www.gov.uk/government/publications/health-protection-report-volume-12-2018/hpr-volume-12-issue-20-news-8-june (2018).
35. Torrone, E. A. et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. *PLoS Med.* **15**, e1002511 (2018).
36. Dehne, K. L. et al. A survey of STI policies and programmes in Europe: preliminary results. *Sex. Transm. Infect.* **78**, 380–384 (2002).
37. Kojima, N., Davey, D. J. & Klausner, J. D. Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. *AIDS* **30**, 2251–2252 (2016).
38. Traeger, M. W. et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. *JAMA* **321**, 1380–1390 (2019).
39. World Health Organization. Prevention and control of seually transmittted infections (STIs) in the era of oral pre-exposure prophylaxis (PrEP) for HIV. Technical Brief. *WHO* https://apps.who.int/iris/bitstream/handle/10665/325908/WHO-CDS-HIV-19.9-eng.pdf?ua=1 (2019).
40. Celum C. Oral pre-exposure prophylaxis (PrEP) for prevention [MOSA3401]. *22nd International AIDS Conference (AIDS 2018)* http://programme.aids2018.org/People/PeopleDetailStandalone/7599 (2018).
41. McCormack, S. et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet* **387**, 53–60 (2016).
42. Morse, S. A. *Neisseria gonorrhoeae*: physiology and metabolism. *Sex. Transm. Dis.* **6**, 28–37 (1979).
43. Rohde, K. H. & Dyer, D. W. Mechanisms of iron acquisition by the human pathogens Neisseria meningitidis and *Neisseria gonorrhoeae*. *Front. Biosci.* **8**, d1186–d1218 (2003).
44. Cole, J. A. Legless pathogens: how bacterial physiology provides the key to understanding pathogenicity. *Microbiology* **158**, 1402–1413 (2012).
45. Sanchez-Buso, L. et al. The impact of antimicrobials on gonococcal evolution. *Nat. Microbiol.* **4**, 1941–1950 (2019).
This genomics paper provides evidence that the modern gonococcal population is not as old as previously anticipated and has been formed by antimicrobial treatment, leading to the emergence of one multidrug-resistant lineage and one multisusceptible lineage with different evolutionary strategies.
46. Tobiason, D. M. & Seifert, H. S. The obligate human pathogen, *Neisseria gonorrhoeae*, is polyploid. *PLoS Biol.* **4**, 1069–1078 (2006).
47. Unemo, M. et al. The novel 2016 WHO *Neisseria gonorrhoeae* reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. *J. Antimicrob. Chemother.* **71**, 3096–3108 (2016).
48. Goodman, S. D. & Scocca, J. J. Identification and arrangement of the DNA sequence recognized in specific transformation of *Neisseria gonorrhoeae*. *Proc. Natl Acad. Sci. USA* **85**, 6982–6986 (1988).
49. Berry, J. L., Cehovin, A., McDowell, M. A., Lea, S. M. & Pelicic, V. Functional analysis of the interdependence between DNA uptake sequence and its cognate ComP receptor during natural transformation in Neisseria species. *PLoS Genet.* **9**, e1004014 (2013).
50. Bennett, J. S. et al. Species status of *Neisseria gonorrhoeae*: evolutionary and epidemiological inferences from multilocus sequence typing. *BMC Biol.* **5**, 35 (2007).
51. Maiden, M. C. et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc. Natl Acad. Sci. USA* **95**, 3140–3145 (1998).
52. Goire, N. et al. Mixed gonococcal infections in a high-risk population, Sydney, Australia 2015: implications

for antimicrobial resistance surveillance? *J. Antimicrob. Chemother.* **72**, 407–409 (2017).
53. Martin, I. M. & Ison, C. A. Detection of mixed infection of *Neisseria gonorrhoeae*. *Sex. Transm. Infect.* **79**, 56–58 (2003).
54. Unemo, M. & Shafer, W. M. Antibiotic resistance in *Neisseria gonorrhoeae*: origin, evolution, and lessons learned for the future. *Ann. NY Acad. Sci.* **1230**, E19–E28 (2011).
55. Piekarowicz, A. et al. Characterization of the dsDNA prophage sequences in the genome of *Neisseria gonorrhoeae* and visualization of productive bacteriophage. *BMC Microbiol.* **7**, 66 (2007).
56. Stohl, E. A., Dale, E. M., Criss, A. K. & Seifert, H. S. *Neisseria gonorrhoeae* metalloprotease NGO1686 is required for full piliation, and piliation is required for resistance to H2O2- and neutrophil-mediated killing. *mBio* **4**, e00399–13 (2013).
57. Biswas, G. D., Sox, T., Blackman, E. & Sparling, P. F. Factors affecting genetic transformation of Neisseria gonorrhoeae. *J. Bacteriol.* **129**, 983–992 (1977).
58. Dehio, C., Gray-Owen, S. D. & Meyer, T. F. The role of neisserial Opa proteins in interactions with host cells. *Trends Microbiol.* **6**, 489–495 (1998).
59. Sadarangani, M., Pollard, A. J. & Gray-Owen, S. D. Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. *FEMS Microbiol. Rev.* **35**, 498–514 (2011).
60. Deo, P. et al. Outer membrane vesicles from Neisseria gonorrhoeae target PorB to mitochondria and induce apoptosis. *PLoS Pathog.* **14**, e1006945 (2018).
61. Massari, P., Ram, S., Macleod, H. & Wetzler, L. M. The role of porins in neisserial pathogenesis and immunity. *Trends Microbiol.* **11**, 87–93 (2003).
62. Madico, G. et al. Factor H binding and function in sialylated pathogenic Neisseriae is influenced by gonococcal, but not meningococcal, porin. *J. Immunol.* **178**, 4489–4497 (2007).
63. Olesky, M., Zhao, S., Rosenberg, R. L. & Nicholas, R. A. Porin-mediated antibiotic resistance in *Neisseria gonorrhoeae*: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. *J. Bacteriol.* **188**, 2300–2308 (2006).
64. Shafer, W. M. et al. in *Efflux-Mediated Antimicrobial Resistance in Bacteria* (eds Li, X. Z., Elkins,C. & Zgurskaya, H.) 439-469 (Adis, Cham, 2016).
65. Hagman, K. E. et al. Resistance of *Neisseria gonorrhoeae* to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. *Microbiology* **141**, 611–622 (1995).
66. Lee, E. H. & Shafer, W. M. The farAB-encoded efflux pump mediates resistance of gonococci to long-chained antibacterial fatty acids. *Mol. Microbiol.* **33**, 839–845 (1999).
67. Hooper, R. R. et al. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. *Am. J. Epidemiol.* **108**, 136–144 (1978).
68. Cohen, M. S. et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. *Lancet* **349**, 1868–1873 (1997).
69. Price, M. A. et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. *Sex. Transm. Dis.* **30**, 516–522 (2003).
70. Melly, M. A., Gregg, C. R. & McGee, Z. A. Studies of toxicity of *Neisseria gonorrhoeae* for human fallopian tube mucosa. *J. Infect. Dis.* **143**, 423–431 (1981).
71. Melly, M. A., McGee, Z. A. & Rosenthal, R. S. Ability of monomeric peptidoglycan fragments from *Neisseria gonorrhoeae* to damage human fallopian-tube mucosa. *J. Infect. Dis.* **149**, 378–386 (1984).
72. Escobar, A., Rodas, P. I. & Acuña-Castillo, C. Macrophage–*Neisseria gonorrhoeae* interactions: a better understanding of pathogen mechanisms of immunomodulation. *Front. Immunol.* **9**, 3044 (2018).
73. Criss, A. K. & Seifert, H. S. A bacterial siren song: intimate interactions between *Neisseria* and neutrophils. *Nat. Rev. Microbiol.* **10**, 178–190 (2012).
74. Massari, P., Ho, Y. & Wetzler, L. M. *Neisseria meningitidis* porin PorB interacts with mitochondria and protects cells from apoptosis. *Proc. Natl Acad. Sci. USA* **97**, 9070–9075 (2000).
75. Muller, A. et al. Targeting of the pro-apoptotic VDAC-like porin (PorB) of *Neisseria gonorrhoeae* to mitochondria of infected cells. *EMBO J.* **19**, 5332–5343 (2000).
76. Shaughnessy, J., Ram, S. & Rice, P. A. Biology of the gonococcus: disease and pathogenesis. *Methods Mol. Biol.* **1997**, 1–27 (2019).
This review describes gonorrhoea, its epidemiology, the structure and function of major surface components involved in pathogenesis, and mechanisms that gonococci use to evade immune responses.
77. Densen, P. Interaction of complement with *Neisseria meningitidis* and *Neisseria gonorrhoeae*. *Clin. Microbiol. Rev.* **2**, S11–S17 (1989).
78. Crew, P. E. et al. Unusual *Neisseria* species as a cause of infection in patients taking eculizumab. *J. Infect.* **78**, 113–118 (2019).
79. Liu, Y., Feinen, B. & Russell, M. W. New concepts in immunity to *Neisseria gonorrhoeae*: innate responses and suppression of adaptive immunity favor the pathogen, not the host. *Front. Microbiol.* **2**, 52 (2011).
80. Boslego, J. W. et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. *Vaccine* **9**, 154–162 (1991).
81. Rotman, E. & Seifert, H. S. The genetics of *Neisseria* species. *Annu. Rev. Genet.* **48**, 405–431 (2014).
82. Bignell, C. & Unemo, M., European STI Guidelines Editorial Board. European guideline on the diagnosis and treatment of gonorrhoea in adults. *Int. J. STD & AIDS* **24**, 85–92 (2012).
83. Ghanem, K. G. Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents *UpToDate.com* https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-neisseria-gonorrhoeae-infection-in-adults-and-adolescents/print (2019).
84. Ison, C. A. Laboratory methods in genitourinary medicine. Methods of diagnosing gonorrhoea. *Genitourin. Med.* **66**, 453–459 (1990).
85. Unemo, M. & Ison, C. in *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (eds Unemo, M. et al.) 21–54 (World Health Organization, 2013).
This comprehensive chapter describes biological sampling, different methods for laboratory detection and antimicrobial susceptibility testing of *N. gonorrhoeae*.
86. Taylor, S. N., DiCarlo, R. P. & Martin, D. H. Comparison of methylene blue/gentian violet stain to Gram's stain for the rapid diagnosis of gonococcal urethritis in men. *Sex. Transm. Dis.* **38**, 995–996 (2011).
87. Papp, J. R. S. J., Gaydos, C. A. & Van Der Pol, B. Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* — 2014. *MMWR Recomm. Rep.* **63**, 1–19 (2014).
88. Dillon, J. R. Sustainable antimicrobial surveillance programs essential for controlling *Neisseria gonorrhoeae* superbug. *Sex. Transm. Dis.* **38**, 899–901 (2011).
89. Starnino, S. D., J. R. Laboratory manual: identification and antimicrobial susceptibility testing of *Neisseria gonorrhoeae* 2nd edn *Co-ordinating Centre for the Gonococcal Antimicrobial Susceptibility Surveillance Program in Latin America and the Caribbean* (2002).
90. Starnino, S. & Dillon, J. R. in *Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus* (eds Unemo, M. et al.)199–218 (World Health Organization, 2013).
91. Dillon, J. R., Carballo, M. & Pauze, M. Evaluation of eight methods for identification of pathogenic Neisseria species: Neisseria-Kwik, RIM-N, Gonobio-Test, Minitek, Gonochek II, GonoGen, Phadebact Monoclonal GC OMNI Test, and Syva MicroTrak Test. *J. Clin. Microbiol.* **26**, 493–497 (1988).
92. Kellogg, J. A. & Orwig, L. K. Comparison of GonoGen, GonoGen II, and MicroTrak direct fluorescent-antibody test with carbohydrate fermentation for confirmation of culture isolates of Neisseria gonorrhoeae. *J. Clin. Microbiol.* **33**, 474–476 (1995).
93. Kulkarni, S., Bala, M. & Risbud, A. Performance of tests for identification of Neisseria gonorrhoeae. *Indian J. Med. Res.* **141**, 833–835 (2015).
94. Centers for Disease Control and Prevention. *Acid Detection Test* http://www.cdc.gov/std/gonorrhea/lab/tests/acid.htm (CDC, 2013).
95. Buchanan, R., Ball, D., Dolphin, H. & Dave, J. Matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for the identification of Neisseria gonorrhoeae. *Clin. Microbiol. Infect.* **22**, 815.e815–815.e817 (2016).
96. Ilina, E. N. et al. Direct bacterial profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for identification of pathogenic *Neisseria*. *J. Mol. Diagn.* **11**, 75–86 (2009).
97. Morel, F. et al. Use of Andromas and Bruker MALDI-TOF MS in the identification of *Neisseria*. *Eur. J. Clin. Microbiol. Infect. Dis* **37**, 2273–2277 (2018).
98. Schmidt, K. et al. Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. *J. Antimicrob. Chemother.* **72**, 104–114 (2017).
99. Hughes, G. I. *et al*. *Guidance for the detection of gonorrhoea in England*. (Public Health England, London, 2014).
100. Tabrizi, S. N. et al. Evaluation of six commercial nucleic acid amplification tests for detection of *Neisseria gonorrhoeae* and other *Neisseria* species. *J. Clin. Microbiol.* **49**, 3610–3615 (2011).
101. Murtagh, M. M. The point-of-care diagnostic landscape for sexually transmitted infections (STIs). *WHO* https://www.who.int/reproductivehealth/topics/rtis/Diagnostic_Landscape_2018.pdf (2018).
This extensive report details point-of-care diagnostic tests for STIs, with special focus on tests in the development pipeline.
102. Whiley, D. M., Tapsall, J. W. & Sloots, T. P. Nucleic acid amplification testing for *Neisseria gonorrhoeae*: an ongoing challenge. *J. Mol. Diagn.* **8**, 3–15 (2006).
103. Alexander, S., da Silva, Coelho, Manuel, F., Varma, R. & Ison, R. C. Evaluation of strategies for confirming *Neisseria gonorrhoeae* nucleic acid amplification tests. *J. Med. Microbiol.* **60**, 909–912 (2011).
104. Venter, J. M. E. et al. Comparison of an in-house real-time duplex PCR assay with commercial HOLOGIC(R) APTIMA assays for the detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in urine and extra-genital specimens. *BMC Infect. Dis.* **19**, 6 (2019).
105. United States Food and Drug Administration. Nucleic Acid Based Tests. *FDA* https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests (2019).
106. Schachter, J., Moncada, J., Liska, S., Shayevich, C. & Klausner, J. D. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. *Sex. Transm. Dis.* **35**, 637–642 (2008).
107. Chernesky, M. et al. Head-to-head comparison of second-generation nucleic acid amplification tests for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* on urine samples from female subjects and self-collected vaginal swabs. *J. Clin. Microbiol.* **52**, 2305–2310 (2014).
108. Jang, D. et al. Comparison of workflow, maintenance, and consumables in the genexpert infinity 80 and panther instruments while testing for *chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Sex. Transm. Dis.* **43**, 377–381 (2016).
109. World Health Organization. *WHO Guidelines for the Treatment of Neisseria gonorrhoeae* (WHO, 2016).
110. Public Health Agency Canada. National Surveillance of Antimicrobial Susceptibilities of *Neisseria gonorrhoeae* - 2016. (Government of Canada 2018).
111. Thakur, S. D. & Dillon, J. R. High levels of susceptibility to new and older antibiotics in *Neisseria gonorrhoeae* isolates from Saskatchewan (2003–15): time to consider point-of-care or molecular testing for precision treatment? Authors' response. *J. Antimicrob. Chemother.* **73**, 829–830 (2018).
112. Allan-Blitz, L. T. et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of *Neisseria gonorrhoeae* in a large health system. *Clin. Infect. Dis.* **64**, 1268–1270 (2017).
113. Ellis, O. et al. A multisite implementation of a real-time polymerase chain reaction assay to predict ciprofloxacin susceptibility in *Neisseria gonorrhoeae*. *Diagn. Microbiol. Infect. Dis.* **94**, 213–217 (2019).
114. Fifer, H., Saunders, J., Soni, S., Sadiq, S. T. & FitzGerald, M. British Association for Sexual Health and HIV national guideline for the management of infection with *Neisseria gonorrhoeae* (BASHH, 2019).
115. Badman, S. G. *et al*. A diagnostic evaluation of a molecular assay used for testing and treating anorectal chlamydia and gonorrhoea infections at the point-of-care in Papua New Guinea. *Clin. Microbiol. Infect.* **25**, 623–627 (2018).
116. Wi, T. E. et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. *J. Int. AIDS Soc.* **22** (Suppl. 6), e25343 (2019).
117. Pai, M., Ghiasi., M. & Pai, N. P. Point-of-care diagnostic testing in global health: what is the point? *Microbe* **10**, 103–107 (2015).
118. Pai, N. P., Vadnais, C., Denkinger, C., Engel, N. & Pai, M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and

middle-income countries. *PLoS Med.* **9**, e1001306 (2012).
119. Peeling, R. W., Holmes, K. K., Mabey, D. & Ronald, A. Rapid tests for sexually transmitted infections (STIs): the way forward. *Sex. Transm. Infect.* **82** (Suppl. 5), v1–v6 (2006).
120. Watchirs Smith, L. A. et al. Point-of-care tests for the diagnosis of *Neisseria gonorrhoeae* infection: a systematic review of operational and performance characteristics. *Sex. Transm. Infect.* **89**, 320–326 (2013).
121. Cristillo, A. D. et al. Point-of-care sexually transmitted infection diagnostics: proceedings of the STAR Sexually Transmitted Infection–Clinical Trial Group Programmatic Meeting. *Sex. Transm. Dis.* **44**, 211–218 (2017).
122. Herbst de Cortina, S., Bristow, C. C., Joseph Davey, D. & Klausner, J. D. A systematic review of point of care testing for *chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *trichomonas vaginalis*. *Infect. Dis. Obstet. Gynecol.* **2016**, 4386127 (2016).
123. Guy, R. J. et al. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. *Sex. Transm. Infect.* **93**, S16–S21 (2017).
124. Vickerman, P., Watts, C., Alary, M., Mabey, D. & Peeling, R. W. Sensitivity requirements for the point of care diagnosis of *chlamydia trachomatis* and *Neisseria gonorrhoeae* in women. *Sex. Transm. Infect.* **79**, 363–367 (2003).
125. Causer, L. M. et al. A field evaluation of a new molecular-based point-of-care test for chlamydia and gonorrhoea in remote aboriginal health services in Australia. *Sex. Health* **12**, 27–33 (2015).
126. Garrett, N. et al. Diagnostic accuracy of the Xpert CT/NG and OSOM trichomonas rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study. *BMJ Open* **9**, e026888 (2019).
127. LeFevre, M. L. Screening for chlamydia and gonorrhea: U.S. preventive services task force recommendation statement. *Ann. Intern. Med.* **161**, 902–910 (2014).
128. Workowski, K. A. & Bolan, G. A., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR. Recomm. Rep.* **64**, 1–137 (2015).
129. Centers for Disease Control and Prevention. *Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update*. (US Public Health Service, 2017).
130. World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006 – 2015 Breaking the chain of transmission. *WHO* https://www.who.int/hiv/pub/toolkits/stis_strategy%5B1%5Den.pdf (2007).
131. Gottlieb, S. L. & Johnston, C. Future prospects for new vaccines against sexually transmitted infections. *Curr. Opin. Infect. Dis.* **30**, 77–86 (2017).
132. Jerse, A. E. & Deal, C. D. Vaccine research for gonococcal infections: where are we? *Sex. Transm. Infect.* **89**, iv63–iv68 (2013).
133. Zhu, W. et al. Vaccines for gonorrhea: can we rise to the challenge? *Front. Microbiol.* **2**, 124 (2011).
134. Edwards, J. L., Jennings, M. P., Apicella, M. A. & Seib, K. L. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. *Crit. Rev. Microbiol.* **42**, 928–941 (2016).
This review describes the status of gonococcal vaccine development and, in particular, focuses on the model systems available to evaluate drug and vaccine candidates.
135. Tramont, E. C. Gonococcal vaccines. *Clin. Microbiol. Rev.* **2**, S74–S77 (1989).
136. Paynter, J. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. *Vaccines* **7**, E5 (2019).
137. Petousis-Harris, H. Impact of meningococcal group B OMV vaccines, beyond their brief. *Hum. Vaccin. Immunother.* **14**, 1058–1063 (2018).
138. Petousis-Harris, H. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. *Lancet* **390**, 1603–1610 (2017).
This study provides a first proof-of-principle for vaccine protection against gonorrhoea, owing to cross-protection by the outer membrane vesicle *Neisseria meningitidis* serogroup B vaccine (MeNZB).
139. Hadad, R. et al. Novel meningococcal 4CMenB vaccine antigens — prevalence and polymorphisms of the encoding genes in *Neisseria gonorrhoeae*. *APMIS* **120**, 750–760 (2012).
140. Beernink, P. T. et al. A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor h binding protein elicits gonococcal bactericidal antibodies. *J. Infect. Dis.* **219**, 1130–1137 (2019).
141. Centers for Disease Control and Prevention. *Expedited partner therapy in the management of sexually transmitted diseases.* (US Department of Health and Human Services, 2006).
142. Parran, T. *Shadow on the Land: Syphilis*. (Reynal & Hitchcock, 1937).
143. Golden, M. R. et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *N. Engl. J. Med.* **352**, 676–685 (2005).
144. Romanowski, B., Robinson, J. & Wong, T. Canadian Guidelines on Sexually Transmitted Infections - Gonococcal Infections Chapter. *Phac-aspc.gc.ca* http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/assets/pdf/section-5-6-eng.pdf (2013).
145. Australasian Sexual Health Alliance (ASHA). Gonorrhoea. *ASHA* http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management (2016).
146. Japanese Society for Sexually Transmitted Infections. Gonococcal infection. Sexually transmitted infections, diagnosis and treatment guidelines 2011. *Jpn J. Sex. Transm. Dis.* **22** (Suppl. 1), 52–59 (2011). In Japanese.
147. Bignell, C. & Fitzgerald, M., Guideline Development Group, British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults, 2011. *Int. J. STD & AIDS* **22**, 541–547 (2011).
148. Boiko, I. et al. Antimicrobial susceptibility of *Neisseria gonorrhoeae* isolates and treatment of gonorrhoea patients in ternopil and dnipropetrovsk regions of Ukraine, 2013–2018. *APMIS* **127**, 503–509 (2019).
149. Unemo, M., Shipitsyna, E. & Domeika, M. Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a *Neisseria gonorrhoeae* antimicrobial susceptibility programme in this region is crucial. *Sex. Transm. Infect.* **86**, 442–444 (2010).
150. Leonard, C. A., Schoborg, R. V., Low, N., Unemo, M. & Borel, N. Pathogenic interplay between chlamydia trachomatis and Neisseria gonorrhoeae that influences management and control efforts — more questions than answers? *Curr. Clin. Microbiol. Rep.* **6**, 182–191 (2019).
151. Handsfield, H. H., McCutchan, J. A., Corey, L. & Ronald, A. R. Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. infectious diseases society of america and the food and drug administration. *Clin. Infect. Dis.* **15** (Suppl. 1), S123–S130 (1992).
152. Hook, E. W. 3rd & Kirkcaldy, R. D. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. *Clin. Infect. Dis.* **67**, 1294–1299 (2018).
153. Unemo, M. et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. *Sex. Health* **16**, 412–425 (2019).
This paper reports the WHO GASP data from 2015 to 2016, confirmed gonorrhoea treatment failures with recommended therapy and international collaborative actions and research efforts essential for the effective management and control of gonorrhoea.
154. Cole, M. J. et al. Is the tide turning again for cephalosporin resistance in *Neisseria gonorrhoeae* in Europe? Results from the 2013 European surveillance. *BMC Infect. Dis.* **15**, 321 (2015).
155. Day, M. J. et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. *BMC Infect. Dis.* **18**, 609 (2018).
156. Harris, S. R. et al. Public health surveillance of multidrug-resistant clones of *Neisseria gonorrhoeae* in Europe: a genomic survey. *Lancet Infect. Dis.* **18**, 758–768 (2018).
This genomics paper provides the first use of joint analysis of WGS and epidemiological data in an international surveillance programme for STIs and a framework for genomic surveillance of gonococci through standardized sampling, use of WGS, and a shared information architecture for interpretation and dissemination by use of open-access software.
157. Kirkcaldy, R. D. et al. *Neisseria gonorrhoeae* antimicrobial susceptibility surveillance — the gonococcal isolate surveillance project, 27 sites, United States, 2014. *MMWR* **65**, 1–19 (2016).
158. Kirkcaldy, R. D., Kidd, S., Weinstock, H. S., Papp, J. R. & Bolan, G. A. Trends in antimicrobial resistance in *Neisseria gonorrhoeae* in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006–June 2012. *Sex. Transm. Infect.* **89**, iv5–iv10 (2013).
159. Ford, J. V. et al. The need to promote sexual health in America: a new vision for public health action. *Sex. Transm. Dis.* **44**, 579–585 (2017).
160. Reed, J. L. et al. Adolescent patient preferences surrounding partner notification and treatment for sexually transmitted infections. *Acad. Emerg. Med.* **22**, 61–66 (2015).
161. Goffman, E. Stigma: notes on the management of spoiled identity (Aronson, J., 1974).
162. Fortenberry, J. D. et al. Relationships of stigma and shame to gonorrhea and HIV screening. *Am. J. Public Health* **92**, 378–381 (2002).
163. Lichtenstein, B. Stigma as a barrier to treatment of sexually transmitted infection in the American deep south: issues of race, gender and poverty. *Soc. Sci. Med.* **57**, 2435–2445 (2003).
164. Tsadik, M., Berhane, Y., Worku, A. & Terefe, W. The magnitude of, and factors associated with, loss to follow-up among patients treated for sexually transmitted infections: a multilevel analysis. *BMJ Open* **7**, e016864 (2017).
165. Tshokey, T. et al. Antibiotic resistance in *Neisseria gonorrhoea* and treatment outcomes of gonococcal urethritis suspected patients in two large hospitals in Bhutan, 2015. *PLoS One* **13**, e0201721 (2018).
166. Schwartz, R. M. et al. Coping with a diagnosis of C. trachomatis or *N. gonorrhoeae*: psychosocial and behavioral correlates. *J. Health Psychol.* **13**, 921–929 (2008).
167. Wong, J. P. H., Chan, K. B. K., Bio-Doku, R. & Mcwatt, S. Risk discourse and sexual stigma: barriers to STI testing, treatment and care among young heterosexual women in disadvantaged neighbourhoods in Toronto. *Can. J. Hum. Sex.* **21**, 74–89 (2012).
168. Morris, J. L. et al. Sexually transmitted infection related stigma and shame among African American male youth: implications for testing practices, partner notification, and treatment. *AIDS Patient Care STDS* **28**, 499–506 (2014).
169. Crenshaw, K. Mapping the margins: intersectionality, identity politics, and violence against women of color. *Stanf. Law Rev.* **43**, 1241–1299 (1991).
170. Unemo, M. et al. Sexually transmitted infections: challenges ahead. *Lancet Infect. Dis.* **17**, e235–e279 (2017).
This very extensive Commission discusses the current key challenges facing the field of STIs and outlines new approaches to improve the clinical management of STIs and public health.
171. Carlton, T. O. & Mayes, S. M. Gonorrhea: not a 'second-class' disease. *Health Soc. Work.* **7**, 301–313 (1982).
172. Wu, D., Hawkes, S. & Buse, K. Prevention of mother-to-child transmission of syphilis and HIV in China: what drives political prioritization and what can this tell us about promoting dual elimination? *Int. J. Gynaecol. Obstet.* **130**, S32–S36 (2015).
173. Cook, J. E., Purdie-Vaughns, V., Meyer, I. H. & Busch, J. T. A. Intervening within and across levels: a multilevel approach to stigma and public health. *Soc. Sci. Med.* **103**, 101–109 (2014).
174. Demczuk, W. et al. Whole-genome phylogenomic heterogeneity of *Neisseria gonorrhoeae* isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. *J. Clin. Microbiol.* **53**, 191–200 (2015).
175. Demczuk, W. et al. Genomic epidemiology and molecular resistance mechanisms of azithromycin-resistant *Neisseria gonorrhoeae* in Canada from 1997 to 2014. *J. Clin. Microbiol.* **54**, 1304–1313 (2016).
176. Grad, Y. H. et al. Genomic epidemiology of *Neisseria gonorrhoeae* with reduced susceptibility to cefixime in the USA: a retrospective observational study. *Lancet Infect. Dis.* **14**, 220–226 (2014).
177. Grad, Y. H. et al. Genomic epidemiology of gonococcal resistance to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in the United States, 2000–2013. *J. Infect. Dis.* **214**, 1579–1587 (2016).

178. Jacobsson, S. et al. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) *Neisseria gonorrhoeae* isolates in Europe from 2009 to 2014. *J. Antimicrob. Chemother.* **71**, 3109–3116 (2016).
179. De Silva, D. et al. Whole-genome sequencing to determine transmission of *Neisseria gonorrhoeae*: an observational study. *Lancet Infect. Dis.* **16**, 1295–1303 (2016).
180. Ezewudo, M. N. et al. Population structure of *Neisseria gonorrhoeae* based on whole genome data and its relationship with antibiotic resistance. *PeerJ.* **3**, e806 (2015).
181. Ryan, L. et al. Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of *Neisseria gonorrhoeae* in Ireland, 2014–2016: focus on extended-spectrum cephalosporins and azithromycin. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 1661–1672 (2018).
182. Eyre, D. W. et al. WGS to predict antibiotic MICs for *Neisseria gonorrhoeae*. *J. Antimicrob. Chemother.* **72**, 1937–1947 (2017).
This genomics paper provides strong evidence that WGS can relatively successfully predict MICs of antimicrobials and AMR in *N. gonorrhoeae.*
183. Golparian, D. et al. Antimicrobial resistance prediction and phylogenetic analysis of *Neisseria gonorrhoeae* isolates using the Oxford Nanopore MinION sequencer. *Sci. Rep.* **8**, 17596 (2018).
184. Eyre, D. W., Golparian, D. & Unemo, M. Prediction of minimum inhibitory concentrations of antimicrobials for Neisseria gonorrhoeae using whole-genome sequencing. *Methods Mol. Biol.* **1997**, 59–76 (2019).
185. Unemo, M. & Althaus, C. L. Fitness cost and benefit of antimicrobial resistance in *Neisseria gonorrhoeae*: multidisciplinary approaches are needed. *PLoS Med.* **14**, e1002423 (2017).
186. Fingerhuth, S. M., Low, N., Bonhoeffer, S. & Althaus, C. L. Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. *BMC Med.* **15**, 142 (2017).
187. Jacobsson, S. et al. WHO laboratory validation of Xpert((R)) CT/NG and Xpert((R)) TV on the GeneXpert system verifies high performances. *APMIS.* **126**, 907–912 (2018).
188. Nudel, K. et al. Transcriptome analysis of *Neisseria gonorrhoeae* during natural infection reveals differential expression of antibiotic resistance determinants between men and women. *mSphere* **3**, e00312–e00318 (2018).
189. Zielke, R. A. et al. Proteomics-driven antigen discovery for development of vaccines against gonorrhea. *Mol. Cell Proteomics* **15**, 2338–2355 (2016).
190. El-Rami, F. E., Zielke, R. A., Wi, T., Sikora, A. E. & Unemo, M. Quantitative proteomics of the 2016 WHO *Neisseria gonorrhoeae* reference strains surveys vaccine candidates and antimicrobial resistance determinants. *Mol. Cell Proteomics* **18**, 127–150 (2019).
191. Unemo, M. & Sikora, A. E. Infection: proof of principle for effectiveness of a gonorrhoea vaccine. *Nat. Rev. Urol.* **14**, 643–644 (2017).
192. Moreau, M. R., Massari, P. & Genco, C. A. The ironclad truth: how in vivo transcriptomics and in vitro mechanistic studies shape our understanding of *Neisseria gonorrhoeae* gene regulation during mucosal infection. *Pathog. Dis.* **75**, https://doi.org/10.1093/femspd/ftx057 (2017).
193. Jerse, A. E. et al. Estradiol-treated female mice as surrogate hosts for *Neisseria gonorrhoeae* genital tract infections. *Front. Microbiol.* **2**, 107 (2011).
194. Sintsova, A. *et al*. Selection for CEACAM receptor-specific binding phenotype during *Neisseria gonorrhoeae* infection of the human genital tract. *Infect. Immun.* **83**, 1372–1383 (2015).
195. Lujan, E., Pajon, R. & Granoff, D. M. Impaired immunogenicity of meningococcal neisserial surface protein A in human complement factor H transgenic mice. *Infect. Immun.* **84**, 452–458 (2016).
196. Low, N. & Unemo, M. Molecular tests for the detection of antimicrobial resistant *Neisseria gonorrhoeae*: when, where, and how to use? *Curr. Opin. Infect. Dis.* **29**, 45–51 (2016).
197. Dona, V., Low, N., Golparian, D. & Unemo, M. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in *Neisseria gonorrhoeae*. *Expert Rev. Mol. Diagn.* **17**, 845–859 (2017).
198. Sadiq, S. T., Mazzaferri, F. & Unemo, M. Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for *Neisseria gonorrhoeae* and mycoplasma genitalium. *Sex. Transm. Infect.* **93**, S65–S68 (2017).
199. Goire, N. et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. *Nat. Rev. Microbiol.* **12**, 223–229 (2014).
200. Basarab, G. S. et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. *Sci. Rep.* **5**, 11827 (2015).
201. Foerster, S. et al. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in *Neisseria gonorrhoeae*. *Front. Microbiol.* **6**, 1377 (2015).
202. Jacobsson, S. et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant *Neisseria gonorrhoeae* isolates suggests a new effective option for oral treatment of gonorrhea. *Antimicrob. Agents Chemother.* **58**, 5585–5588 (2014).
203. Taylor, S. N. et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. *N. Engl. J. Med.* **379**, 1835–1845 (2018).
204. Foerster, S. *et al*. In vitro antimicrobial combination testing and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for *Neisseria gonorrhoeae*. *J. Antimicrob. Chemother*. https://doi.org/10.1093/jac/dkz376 (2019)
205. Jacobsson, S., Golparian, D., Scangarella-Oman, N. & Unemo, M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR *Neisseria gonorrhoeae*. *J. Antimicrob. Chemother.* **73**, 2072–2077 (2018).
206. Scangarella-Oman, N. E. *et al*. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by *Neisseria gonorrhoeae*. *Antimicrob. Agents Chemother*. **62**, e01221–18 (2018).
207. Taylor, S. N. et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. *Clin. Infect. Dis.* **67**, 504–512 (2018).
208. Jacobsson, S., Paukner, S., Golparian, D., Jensen, J. S. & Unemo, M. In vitro activity of the novel pleuromutilin lefamulin (bc-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant *Neisseria gonorrhoeae*. *Antimicrob. Agents Chemother.* **61**, e01497–17 (2017).
209. Paukner, S., Gruss, A. & Jensen, J. S. In vitro activity of lefamulin against sexually transmitted bacterial pathogens. *Antimicrob. Agents Chemother.* **62**, e02380–17 (2018).
210. Jacobsson, S., Mason, C., Khan, N., Meo, P. & Unemo, M. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea? *J. Antimicrob. Chemother.* **74**, 1591–1594 (2019).
211. Kong, F. Y. S., Horner, P., Unemo, M. & Hocking, J. S. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. *J. Antimicrob. Chemother.* **74**, 1157–1166 (2019).
This paper provides a detailed overview of the pharmacokinetics of antimicrobials used to treat STIs and how factors related to the drug, human and organism can affect treatment outcomes.
212. Lenz, J. D. & Dillard, J. P. Pathogenesis of *Neisseria gonorrhoeae* and the host defense in ascending infections of human fallopian tube. *Front. Immunol.* **9**, 2710 (2018).
213. Lucas, C. T., Chandler, F. Jr., Martin, J. E. Jr & Schmale, J. D. Transfer of gonococcal urethritis from man to chimpanzee. An animal model for gonorrhea. *JAMA* **216**, 1612–1614 (1971).
214. Cohen, M. S. & Cannon, J. G. Human experimentation with *Neisseria gonorrhoeae*: progress and goals. *J. Infect. Dis.* **179** (Suppl. 2), S375–S379 (1999).
215. Chow, E. P. et al. Antiseptic mouthwash against pharyngeal *Neisseria gonorrhoeae*: a randomised controlled trial and an in vitro study. *Sex. Transm. Infect.* **93**, 88–93 (2017).
216. Liu, Y. et al. Experimental vaccine induces Th1-driven immune responses and resistance to *Neisseria gonorrhoeae* infection in a murine model. *Mucosal Immunol.* **10**, 1594–1608 (2017).
217. Kenyon, C., Buyze, J., Spiteri, G., Cole, M. J. & Unemo, M. Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in *Neisseria gonorrhoeae* in 24 European countries: an ecological analysis. *J. Infect. Dis*. https://doi.org/10.1093/infdis/jiz153 (2019).
218. Tomberg, J. et al. Alanine 501 mutations in penicillin-binding protein 2 from *Neisseria gonorrhoeae*: structure, mechanism, and effects on cephalosporin resistance and biological fitness. *Biochemistry* **56**, 1140–1150 (2017).
219. Tomberg, J., Unemo, M., Davies, C. & Nicholas, R. A. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in *Neisseria gonorrhoeae*: role of epistatic mutations. *Biochemistry* **49**, 8062–8070 (2010).
220. Tomberg, J., Unemo, M., Ohnishi, M., Davies, C. & Nicholas, R. A. Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from *Neisseria gonorrhoeae* strain H041. *Antimicrob. Agents Chemother.* **57**, 3029–3036 (2013).
221. Lee, H. et al. Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in *Neisseria gonorrhoeae* in Korea. *J. Antimicrob. Chemother.* **70**, 2536–2542 (2015).
222. Olsen, B. et al. Antimicrobial susceptibility and genetic characteristics of *Neisseria gonorrhoeae* isolates from Vietnam, 2011. *BMC Infect. Dis.* **13**, 40 (2013).
223. Whiley, D. M. et al. Reduced susceptibility to ceftriaxone in *Neisseria gonorrhoeae* is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. *J. Antimicrob. Chemother.* **65**, 1615–1618 (2010).
224. Ohnishi, M. et al. Is *Neisseria gonorrhoeae* initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. *Antimicrob. Agents Chemother.* **55**, 3538–3545 (2011).
This paper describes the identification and verification of the first global extensively drug-resistant and high-level ceftriaxone-resistant gonococcal strain that caused a ceftriaxone treatment failure in Japan.
225. Camara, J. et al. Molecular characterization of two high-level ceftriaxone-resistant *Neisseria gonorrhoeae* isolates detected in Catalonia, Spain. *J. Antimicrob. Chemother.* **67**, 1858–1860 (2012).
226. Unemo, M. et al. High-level cefixime- and ceftriaxone-resistant *Neisseria gonorrhoeae* in France: novel penA mosaic allele in a successful international clone causes treatment failure. *Antimicrob. Agents Chemother.* **56**, 1273–1280 (2012).
227. Gianecini, R., Oviedo, C., Stafforini, G. & Galarza, P. *Neisseria gonorrhoeae* resistant to ceftriaxone and cefixime, Argentina. *Emerg. Infect. Dis.* **22**, 1139–1141 (2016).
228. Deguchi, T. et al. New clinical strain of *Neisseria gonorrhoeae* with decreased susceptibility to ceftriaxone, Japan. *Emerg. Infect. Dis.* **22**, 142–144 (2016).
229. Nakayama, S. et al. New ceftriaxone- and multidrug-resistant *Neisseria gonorrhoeae* strain with a novel mosaic pena gene isolated in Japan. *Antimicrob. Agents Chemother.* **60**, 4339–4341 (2016).
230. Lahra, M. M. *et al*. Cooperative recognition of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain. *Emerg. Infect. Dis*. **24**, https://doi.org/10.3201/eid2404.171873 (2018).
231. Lefebvre, B. *et al*. Ceftriaxone-resistant *Neisseria gonorrhoeae*, Canada, 2017. *Emerg. Infect. Dis*. **24**, https://doi.org/10.3201/eid2402.171756 (2018).
232. Terkelsen, D. *et al*. Multidrug-resistant *Neisseria gonorrhoeae* infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. *Euro Surveill* **22**, https://doi.org/10.2807/1560-7917.ES.2017.22.42.17-00659 (2017).
233. Poncin, T. *et al*. Multidrug-resistant *Neisseria gonorrhoeae* failing treatment with ceftriaxone and doxycycline in France, November 2017. *Euro Surveill* **23**, https://doi.org/10.2807/1560-7917.ES.2018.23.21.1800264 (2018).
234. Golparian, D. *et al*. Multidrug-resistant *Neisseria gonorrhoeae* isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. *Euro Surveill* **23**, https://doi.org/10.2807/1560-7917.ES.2018.23.47.1800617 (2018).
235. Eyre, D. W. *et al*. Detection in the United Kingdom of the *Neisseria gonorrhoeae* FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018.

Euro Surveill **24**, https://doi.org/10.2807/1560-7917.ES.2019.24.10.1900147 (2019).
236. Eyre, D. W. *et al*. Gonorrhoea treatment failure caused by a *Neisseria gonorrhoeae* strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. *Euro Surveill* **23**, https://doi.org/10.2807/1560-7917.ES.2018.23.27.1800323 (2018).
This paper describes the identification of the first global gonococcal strain with combined ceftriaxone and high-level azithromycin resistance that caused a ceftriaxone treatment failure in the UK.
237. Whiley, D. M., Jennison, A., Pearson, J. & Lahra, M. M. Genetic characterisation of *Neisseria gonorrhoeae* resistant to both ceftriaxone and azithromycin. *Lancet Infect. Dis.* **18**, 717–718 (2018).
238. Jennison, A. V. *et al*. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin-resistant *Neisseria gonorrhoeae* cases, United Kingdom and Australia, February to April 2018. *Euro Surveill* **24**, https://doi.org/10.2807/1560-7917.ES.2019.24.8.1900118 (2019).
239. Ko, K. K. K. et al. First case of ceftriaxone-resistant multidrug-resistant *Neisseria gonorrhoeae* in Singapore. *Antimicrob. Agents Chemother* **63**, e06224-18 (2019).
240. Lee, K. et al. Clonal expansion and spread of the ceftriaxone-resistant *Neisseria gonorrhoeae* strain FC428, identified in Japan in 2015, and closely related isolates. *J. Antimicrob. Chemother* **74**, 1812–1819 (2019).
241. Fifer, H. et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. *N. Engl. J. Med.* **374**, 2504–2506 (2016).
This study reports on the first global failure of dual antimicrobial therapy (ceftriaxone plus azithromycin) in the treatment of gonorrhoea.
242. Chen, S. C., Han, Y., Yuan, L. F., Zhu, X. Y. & Yin, Y. P. Identification of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain FC428, China. *Emerg. Infect. Dis.* **25**, 1427–1429 (2019).
243. Poncin, T. *et al*. Two cases of multidrug-resistant *Neisseria gonorrhoeae* related to travel in south-eastern Asia, France, June 2019. *Euro Surveill* **24**, https://doi.org/10.2807/1560-7917.ES.2019.24.36.1900528 (2019).
244. Morse, S. A. The biology of the gonococcus. *CRC Crit. Rev. Microbiol.* **7**, 93–189 (1978).
245. Tonjum, T. & Koomey, M. The pilus colonization factor of pathogenic neisserial species: organelle biogenesis and structure/function relationships — a review. *Gene* **192**, 155–163 (1997).
246. Maier, B., Potter, L., So, M., Seifert, H. S. & Sheetz, M. P. Single pilus motor forces exceed 100 pN. *Proc. Natl Acad. Sci. USA* **99**, 16012–16017 (2002).
247. Stern, A., Brown, M., Nickel, P. & Meyer, T. F. Opacity genes in *Neisseria gonorrhoeae*: control of phase and antigenic variation. *Cell* **47**, 61–71 (1986).
248. James, J. F. & Swanson, J. Studies on gonococcus infection. XIII. Occurrence color/opacity colonial variants in clinical cultures. *Infect. Immun.* **19**, 332–340 (1978).
249. Jerse, A. E. et al. Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. *J. Exp. Med.* **179**, 911–920 (1994).
250. Rice, P. A., Vayo, H. E., Tam, M. R. & Blake, M. S. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant *Neisseria gonorrhoeae* by immune serum. *J. Exp. Med.* **164**, 1735–1748 (1986).
251. Mandrell, R. E. et al. In vitro and in vivo modification of *Neisseria gonorrhoeae* lipooligosaccharide epitope structure by sialylation. *J. Exp. Med.* **171**, 1649–1664 (1990).
252. Gaydos, C. A. et al. Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and *Neisseria gonorrhoeae*. *J. Clin. Microbiol.* **48**, 3236–3243 (2010).
253. Levett, P. N. et al. Evaluation of three automated nucleic acid amplification systems for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in first-void urine specimens. *J. Clin. Microbiol.* **46**, 2109–2111 (2008).
254. Gaydos, C. A. et al. Performance of the cepheid CT/NG xpert rapid PCR test for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J. Clin. Microbiol.* **51**, 1666–1672 (2013).
255. Tabrizi, S. N. et al. Analytical evaluation of GeneXpert CT/NG, the first genetic point-of-care assay for simultaneous detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. *J. Clin. Microbiol.* **51**, 1945–1947 (2013).
256. Bromhead, C., Miller, A., Jones, M. & Whiley, D. Comparison of the cobas 4800 CT/NG test with culture for detecting *Neisseria gonorrhoeae* in genital and nongenital specimens in a low-prevalence population in New Zealand. *J. Clin. Microbiol.* **51**, 1505–1509 (2013).
257. Rockett, R. et al. Evaluation of the cobas 4800 CT/NG test for detecting *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Sex. Transm. Infect.* **86**, 470–473 (2010).
258. Van Der Pol, B., Williams, J. A., Fuller, D., Taylor, S. N. & Hook, E. W. 3rd Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. *J. Clin. Microbiol.* **55**, 155–164 (2017).
259. Masek, B. J. et al. Performance of three nucleic acid amplification tests for detection of *chlamydia trachomatis* and *Neisseria gonorrhoeae* by use of self-collected vaginal swabs obtained via an internet-based screening program. *J. Clin. Microbiol.* **47**, 1663–1667 (2009).
260. Moncada, J., Schachter, J., Liska, S., Shayevich, C. & Klausner, J. D. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by use of nucleic acid amplification tests. *J. Clin. Microbiol.* **47**, 1657–1662 (2009).
261. Golparian, D., Tabrizi, S. N. & Unemo, M. Analytical specificity and sensitivity of the APTIMA Combo 2 and APTIMA GC assays for detection of commensal *Neisseria* species and *Neisseria gonorrhoeae* on the gen-probe panther instrument. *Sex. Transm. Dis.* **40**, 175–178 (2013).

Acknowledgements
The authors are grateful to S. Jacobsson (Örebro University Hospital and Örebro University) and S. Perera and N. Parmar (University of Saskatchewan) for technical assistance with preparing this manuscript.

Author contributions
Introduction (M.U.); Epidemiology (F.N.); Mechanisms/pathophysiology (H S.S.); Diagnosis, screening and prevention (J.-A.R.D.); Management (E.W.H.III); Quality of life (S.H.); Outlook (M.U.); Overview of Primer (M.U.).

Competing interests
All authors declare no competing interests.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reviewer information
Nature Reviews Disease Primers thanks G. Hughes, S. Sood and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

RELATED LINKS
World Bank Income Classification: https://databank.worldbank.org/reports.aspx?source=2&series=NY.GNP.PCAP.CD&country=